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Abstract  
Blood transfusions can be life-saving in dogs and cats, but they are not without risk. 
Transfusion-related complications occur despite following expert recommendations on blood 
banking and transfusion administration. The risk of these complications is likely exacerbated 
when expert recommendations are neglected. Prior to our survey of Australian veterinarians, 
there were no published reports outlining common blood banking or transfusion practices in 
Australia. We found Australian veterinary blood banking and transfusion practices were 
largely inconsistent with expert recommendations. For example, only around half of 
veterinarians surveyed compatibility-tested dogs and cats prior to transfusion, and more than 
half pre-medicated animals prior to transfusion. The causes for the inconsistences must be 
identified and addressed to align blood banking and transfusion practices with expert 
recommendations, with the overall goal of decreasing transfusion-related complications in 
dogs and cats.  
Even with optimal blood banking practices, transfusion-related complications 
including post-transfusion inflammation can occur. Inflammatory mediators are known to 
accumulate in blood during storage, and a pre-storage blood banking technique, 
leukoreduction, prevents this accumulation. Our randomised, blinded, interventional clinical 
trial was designed to determine if leukoreduction, compared with no leukoreduction, 
decreases inflammatory biomarker concentrations over time in critically ill dogs. We found no 
significant difference in the concentrations of inflammatory biomarkers over time between 
the two groups, however the heterogeneity of our small population likely precluded us from 
finding a difference. Our randomisation and blinding protocol was successful, and together 
with the data to now power a larger study, we can plan a trial to determine if leukoreduction 
will help decrease post-transfusion inflammation in critically ill dogs.  
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In conclusion, we have found that there is a high risk for transfusion-related 
complications in dogs and cats due to poor alignment with veterinary expert 
recommendations on blood banking and transfusion administration. Additionally, there may 
still be room to improve upon expert recommendations on blood banking to help decrease 
the risk for transfusion-related inflammation with the implementation of leukoreduction, 
however additional research is required.  
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Although often a life-saving intervention, transfusing blood to a patient can 
result in life-threatening complications, in part due to a transfusion-triggered 
inflammatory response. Some of these inflammatory responses are sub-clinical, while 
others manifest as different forms of transfusion reactions that increase patient 
morbidity and mortality.1-4 Strategies aimed at decreasing the development of 
transfusion-triggered inflammation include optimising both blood banking techniques 
and peri-transfusion administration processes. The overall goal of optimisation is 
mitigation of inflammation and improved patient outcome. 
While there are published review articles and textbook chapters written by 
experts in the field of veterinary transfusion medicine, the only open-access, evidence-
based, peer-reviewed consensus statements to inform the wider veterinary 
community of ideal transfusion practices are of very limited scope, rather than broadly 
comprehensive.3, 5-7 We postulated that this void might impact current Australian 
veterinary blood banking and transfusion practices, leading to inconsistencies 
between best practice and actual practice. However, we found that there has been no 
evaluation of blood banking or transfusion practices amongst Australian veterinarians 
to explore this question. Gaining a better understanding of current practice in Australia 
is first required before we can then further explore the links between sub-optimal 
transfusion-related practices and the risk of transfusion-triggered inflammation in 
Australian small animal patients. 
In people, despite strict adherence to expert-generated, evidence-based, peer-
reviewed consensus statements and guidelines on blood banking and transfusion 
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practices, transfusion-related complications still occur. One cause is due to 
accumulation of inflammatory mediators within blood bags during storage.8-12 There 
is recent evidence in veterinary medicine that a blood banking technique known as 
leukoreduction, can prevent inflammatory biomarker accumulation in canine blood 
bags over time.8, 11 In people, several randomised clinical trials have shown 
leukoreduction to be beneficial in decreasing transfusion-related complications.13-20 
However, while there is experimental evidence in healthy dogs that leukoreduction 
can decrease transfusion-triggered inflammation,21, 22 randomised clinical trials 
assessing the effect of leukoreduction on inflammation in critically ill veterinary 
patients are lacking. Assessing the efficacy of blood banking techniques like 
leukoreduction to decrease the risk of transfusion-related complications in veterinary 
patients will help shape future expert recommendations on transfusion practices 














1. To describe small animal transfusion practices in Australia, including access to 
blood products, and frequency of pre-transfusion compatibility testing and 
medication administration. (Chapter 3). 
2. To develop a randomised blinded controlled clinical trial to compare 
concentrations of inflammatory biomarkers over time in critically ill dogs 
administered either leukoreduced or non-leukoreduced packed red blood cells 
(RBC) (Chapter 4). 
 
1.3. Hypotheses 
1. Many blood banking and transfusion practices reported by Australian veterinarians 
will be different to what is recommended by experts in veterinary transfusion 
medicine.  
2. Use of leukoreduced RBC, compared with non-leukoreduced RBC, will prevent 
significant increases in concentrations of inflammatory biomarkers following 
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2. Chapter 2: A literature review: Searching for a link between blood banking and transfusion 
practices, and transfusion-triggered inflammation  
Transfusion-related complications may occur and may increase patient morbidity and 
mortality. One transfusion-related complication is transfusion-triggered inflammation, which 
varies in severity from mild signs to potentially fatal reactions. Most commonly, a reaction 
occurs due to an immune response mounted by the transfusion recipient to the contents 
within the blood product. Within the blood product, storage lesions or pro-inflammatory 
cytokines can be generated, and when transfused, results in a post-transfusion inflammatory 
response in recipients. Possible causes mediating these reactions include type of blood 
product transfused, length of storage of blood product prior to transfusion, and if the blood 
product has undergone any processing prior to transfusion. Another way that a transfusion 
reaction can occur is via administrative errors in blood banking and transfusion practices. 
These include blood collection, handling, storage and transfusion practices, particularly more 
so if they are not performed aligned with expert recommendations. As such, optimising blood 
banking procedures is one possible way to decrease such transfusion reactions. Recent 
studies have shown promising results in a blood processing technique called leukoreduction 
in reducing post-transfusion inflammation in recipients.1, 2  
 
2.1. Transfusions elicit an inflammatory response, which can vary widely in severity 
Blood transfusions routinely save the lives of critically ill patients. While blood 
products are resources of unique cells and proteins, the unavoidable variability of their 
contents leads to an immune response within the transfusion recipient. This response can 
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be clinically silent, where evidence is only found when inflammatory biomarkers are 
assessed. In more severe cases, however, it can lead to adverse events known as 
transfusion reactions. Transfusion reactions are described as any complication seen within 
the blood product recipient that is temporally associated with a blood transfusion. A 
reaction can arise due to a recipient’s physiologic response to the cellular or soluble 
contents of the blood product, or can occur due to an administration error. Importantly, 
all transfusion reactions will increase patient morbidity, and nearly all are associated with 
the development of systemic inflammation. In fact, it is commonly the recipient’s 
inflammatory response that prompts the recognition and identification of a specifically 
defined transfusion reaction. To this end, the focus of this section will be on detailing how 
transfusion reactions arise from transfusion-triggered inflammation, and how blood 
product and transfusion recipient characteristics contribute to the development of this 
inflammatory response.  
 
2.1.1. Mild transfusion-triggered inflammatory responses are clinically silent  
Allogenic blood transfusions likely initiate some degree of inflammatory response 
in all recipients, however evidence of this is not always clinically apparent. Very mild 
transfusion-triggered inflammation may only be detected when biomarkers of 
inflammation are assessed. Also, the underlying diseases of critically ill transfusion 
recipients may have triggered clinical evidence of inflammation, and additional 
transfusion-triggered inflammation may go unnoticed. Finally, the array of different 
medications and therapeutic interventions to which critically ill patients are exposed 
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concomitant with transfusions can further muddy the waters as to why a patient may be 
manifesting clinical signs of inflammation. 
In critically-ill people, blood transfusions have been shown to cause acute 
inflammation evidenced by post-transfusion leukocytosis and elevations in pro-
inflammatory cytokines.3-5 One prospective study found an immediate post-RBC 
transfusion neutrophilia developed in 45 of 50 intensive care unit patients, which 
persisted for 12 hours. None of the patients had significant changes in their eosinophil 
count, nor were any observed to display signs consistent with an allergic reaction.6 The 
findings of this study were similar to another study also performed in critically ill patients, 
where 76% of non-septic patients developed post-transfusion leukocytosis, measured by 
increased neutrophil count. In addition, a positive correlation was identified between 
leukocytosis and IL-8 concentrations in the stored RBC units. Similar to the previous study, 
the patient population that developed an acute and transient leukocytosis did not display 
any clinical signs consistent with an allergic reaction.7 
This mild transfusion-triggered inflammatory response has also been 
demonstrated experimentally in healthy dogs following transfusion of stored autologous 
blood. In one study, investigators found an inflammatory response characterised by 
increased concentrations of circulating segmented neutrophils, fibrinogen, and C-reactive 
protein (CRP) following transfusion of 21 day old RBC.8 In a second study, a similar pro-
inflammatory response was observed in healthy research dogs transfused 28 day old RBC, 
evidenced by  significant elevations in the concentrations of circulating neutrophils and 
the pro-inflammatory cytokine monocyte chemoattractant protein-1 (MCP-1)RBC.9 The 
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results of both studies demonstrate that stored RBC transfusions can induce inflammation 
in healthy dogs without inducing the clinical signs of a transfusion reaction such as 
changes in heart rate, respiratory rate or rectal temperature. As to whether similar 
inflammatory responses occur in either healthy cats or critically ill canine or feline 
transfusion recipients remains to be demonstrated.   
 
2.1.2. More severe transfusion-triggered inflammatory responses cause transfusion reactions 
The more severe transfusion-triggered inflammatory response causing blood 
transfusion reactions are immunologic in origin. Broadly, these reactions can be classified 
as haemolytic, febrile and allergic reactions.10, 11 These acute transfusion reactions are the 
clinical evidence of more significant transfusion-triggered inflammation. Other examples 
of acute immunologic transfusion reactions include type I hypersensitivity reactions, 
febrile non-haemolytic transfusion reactions (FNHTR), transfusion-related acute lung 
injury (TRALI), and acute haemolytic transfusion reactions (AHTR).12, 13 The type of 
inflammatory response and degree of inflammation vary and are dependent on specific 
recipient and blood product characteristics. As such, clinical signs that can range from mild 
and non-life-threatening, such as fever, erythema, and urticaria, to severe, such as 
bradycardia, hypotension, and death.10, 11 Two of the more common transfusion reactions 
arising from a transfusion-triggered inflammatory response are FNHTR and TRALI.10, 14, 15 
Additionally, while AHTR is not very common, it has a very high potential to result in 
death.10, 12 All three of these reactions are described in more detail below.  
 
 20 
2.1.2.1. Febrile non-haemolytic transfusion reactions (FNHTR) 
Febrile non-haemolytic transfusion reactions are defined as a rise in temperature 
of at least 1°C during or shortly after a blood transfusion. In people, FNHTR reportedly 
occurs with 0.12-6.8% of RBC transfusions.16, 17 In veterinary patients, the frequency of 
FNHTR is poorly reported. A recent retrospective study from a university teaching hospital 
reported an FNHTR incidence of 24% in 211 dogs that received RBC transfusions. The 
definition of FNHTR this study employed for diagnosis was unconventional, stating FNHTR 
occurred in dogs with an absolute rectal temperature of >39°C, instead using a change in 
temperature over time. Hence this study likely over-reported the occurrence of febrile 
reactions, as some dogs may have had an elevated temperature prior to receiving a blood 
transfusion. In addition, not all recipients had their temperatures closely monitored, and 
consequently, vital data may have been missed.18 Possible factors contributing to the wide 
variations in reported incidences in people and dogs include variability in definition of 
temperature to diagnose FNHTR, age and type of blood product, as well as presence of 
inflammatory components within the blood product.15  
In people, clinical signs of FNHTR are mild and often self-limiting, and FNHTR has 
been reported to be among the most frequent adverse reactions to a transfusion.14, 15 This 
acute immunologic reaction occurs when recipients are transfused inflammatory 
cytokines released from blood donor leukocytes within blood products, or as a reaction 
against residual donor leukocytes.10, 11, 15 The pro-inflammatory pyrogenic cytokines 
commonly associated with FNHTR in people are tumour necrosis factor-α (TNF-α), 
interleukin-1 (IL-1β) and interleukin-6 (IL-6), and these have been shown to accumulate in 
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human blood products.3-5, 19 Additionally, while not a pyrogenic cytokine, interleukin-8 (IL-
8), an inflammatory chemokine, has been found to accumulate in canine RBC overtime.20-
22 These mediators of inflammation are synthesised and released from leukocytes present 
within the stored blood product, and accumulate overtime during storage.23-25 When they 
are transfused to a recipient, some can act directly on the central nervous system to elicit 
a fever. Additionally, the transfused pro-inflammatory mediators will initiate an acute 
phase response including the endogenous generation of pyrogenic cytokines.5, 7, 23, 24, 26, 27 
Consequently, through the action of both exogenous and endogenous pyrogenic 
cytokines, FNHTR can arise. 
Two early investigations on FNHTR demonstrated that FNHTR in recipients was 
caused by transfusion of bioactive mediators within the supernatant plasma portion of 
platelet concentrates. In the first study, inflammatory mediators known as cytokines were 
found to accumulate in platelet and RBC products over time.16 In a follow up study, platelet 
concentrates were first divided into separate cellular and supernatant plasma 
components, after which each was transfused to a different thrombocytopenic patient. 
They found that patients who received the cytokine-rich supernatant plasma component 
were significantly more likely to develop FNHTR than those receiving the cellular 
component. More importantly, they demonstrated a strong positive correlation between 
FNHTR and plasma supernatant concentrations of IL-1β and IL-6.28 Overall, the two studies 
demonstrated FNHTR associated with platelet transfusions were caused by transfusion of 
bioactive mediators present within the supernatant of the platelet product. Although 
early studies of post-transfusion inflammation were focused on platelet products, there is 
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now a body of research showing various pro-inflammatory cytokines are present within 
human and canine blood products, and when transfused to a recipient, can result in 
transfusion reactions like FNHTR.20, 22, 26, 29  
In people, few studies have evaluated inflammatory biomarker concentrations in 
pre- and post-transfusion plasma samples from patients that developed an FNHTR. In one 
study where 60 patients developed an FNHTR following RBC transfusion, significant 
increases were found in post-transfusion plasma IL-6 and IL-8 levels.30 A more recent study 
had similar findings where plasma IL-6 levels were significantly increased in the 22 
patients that developed an FNHTR post-transfusion, however other inflammatory 
cytokines evaluated such as IL-8, IL-1β, and TNF-α did not significantly increase.31 
There are limited studies evaluating the impact of FNHTR on patient outcomes. 
Although FNHTRs are generally benign events, the development of fever during or shortly 
after a transfusion would prompt clinicians to investigate for other more severe reactions 
such as AHTR or bacterial contamination of the blood product. This investigation is costly 
to the health care system, and can often result in discontinuation of the transfusion and 
wasting of the blood product.  A recent haemovigilance study in Canada evaluated the 
impact of FNHTR on patients and hospitals.  The study reported greater than 90% of 
transfusions were interrupted for evaluation, with more than 40% of blood products 
incompletely transfused. Also, 79% of patients that developed FNHTR had blood cultures 
performed, and approximately 25% underwent thoracic imaging within 48 hours. 
Furthermore, the additional length of stay was a median of 2 days for patients that 
developed FNHTR.15 While it has not been shown that FNHTR impacts mortality in people, 
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patient morbidity certainly is affected. There are no current studies evaluating the impact 
of FNHTR in dogs and cats. 
 
2.1.2.2. Transfusion-related acute lung injury (TRALI)  
While FNHTR are typically non-life-threatening consequences of transfusion-
triggered inflammation, a separate transfusion-initiated inflammatory process, known as 
a transfusion-related acute lung injury (TRALI), has the potential to be fatal.32 Transfusion-
related acute lung injury is defined as the acute development of diffuse non-cardiogenic 
pulmonary oedema causing hypoxaemia that develops during or within six hours of blood 
transfusion in people.33-37 Other clinical features of TRALI include tachypnoea, fever, 
hypotension and transient leukopenia.36-38 In people, the pathophysiology of TRALI is not 
well understood, but a biphasic inflammatory response has been proposed.39 Typically, a 
comorbidity to prompt an inflammatory response occurs prior to a blood transfusion. This 
inflammatory response activates the pulmonary vascular endothelium, leading to the 
accumulation of primed neutrophils in the pulmonary capillary beds.40-43 The second 
inflammatory response arises when anti-leukocyte antibodies and bioactive lipids within 
the blood transfusion product activate the primed pulmonary neutrophils and pulmonary 
endothelial cells. The end result is leakage of protein-rich plasma and leukocytes into 
pulmonary interstitium and alveoli, causing diffuse pulmonary oedema.40-43 Neutrophilic 
lung injury can also occur independent of neutrophil priming where an endogenous 
stimulus may activate the pulmonary endothelial cells.39, 42 
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While TRALI can occur in any transfusion recipient, especially if a comorbidity to 
prompt an inflammatory response is present, multiple studies have shown that cardiac 
surgery patients may be at increased risk of developing TRALI, and several reasons have 
been proposed. The pre-transfusion inflammatory insult to induce activation of the 
pulmonary endothelium is caused by injury to the pulmonary vasculature resulting from 
non-ventilated lung for several hours. The neutrophils are then primed by 
cardiopulmonary bypass, which is often used during surgery for these patients, and the 
primed neutrophils accumulate within the pulmonary capillary beds.44 As these patients 
often require multiple blood product transfusions during surgery, the second 
inflammatory responses arise when inevitable transfusions of many anti-leukocyte 
antibodies and bioactive lipids within the blood products occur, ultimately resulting in 
diffuse pulmonary oedema. 
The generation of plasma pro-inflammatory cytokines following transfusions is 
another risk factor for developing TRALI, and elevations of such endogenous inflammation 
have been demonstrated in cardiac surgical patients in several studies. A study performed 
in 114 cardiac surgical patients reported plasma IL-6 levels were significantly higher in 
patients that received transfusions. The investigators also measured IL-6 concentrations 
in the units of RBC and interestingly, IL-6 was undetectable in all samples, therefore 
concluding that IL-6 was produced endogenously.45 Increased plasma Il-6 levels was 
similarly reported in another study performed in 29 patients undergoing cardiopulmonary 
bypass that received RBC transfusions.46 Additionally, elevations of pro-inflammatory 
cytokines were also found in bronchoalveolar lavage fluid (BALF) in a similar population of 
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patients. These group of investigators evaluated post-transfusion inflammation in 45 
patients undergoing cardiac surgery. Patients were enrolled into 3 groups; if they received 
1-2 units of RBC (n=18), at least 5 units of RBC (n=10), and a control group that did not 
receive transfusions (n=17). The results of their study revealed patients that received RBC 
transfusions had elevated BALF levels of TNF-α, IL-1β and IL-8, and if multiple transfusions 
were administered, plasma TNF-α was increased compared to control patients.47 These 
studies show evidence that transfusions increase the incidence of TRALI, particularly in 
patients that received more blood products. However, it remains unclear if the presence 
of these pro-inflammatory cytokines affects the risk of TRALI in these cardiac surgical 
patients. A large case-control study reported an incidence of TRALI in 3.3% of their 
transfused cardiac surgical patients compared with controls that did not receive 
transfusions. The investigators also found that patients that developed TRALI had received 
more blood products compared with controls.48 In addition, reports of TRALI are not 
limited to cardiac surgical patients, but also in critically ill people admitted into the ICU. In 
a large prospective cohort study that enrolled 900 patients in the ICU, the investigators 
reported an 8% incidence of TRALI in a critically-ill population.49  While the underlying 
cause for a difference in the incidences between the two study populations remains 
unclear, these studies demonstrated that transfusions can result in the development of 
inflammation in the lungs manifested as TRALI in a wide range of critically ill patients.  
The lack of veterinary-specific guidelines in the early days would have made 
diagnosing TRALI challenging, and to date, TRALI remains poorly documented in the 
veterinary literature. Prior to 2007, clinical veterinary publications of ALI/ARDS were 
 26 
ALI: Acute lung injury, SIRS: systemic inflammatory response syndrome, PaO2: partial pressure of arterial 
oxyegen, FiO2: fraction of inspired oxygen, PAO2: partial pressure of alveolar oxygen, PaCO2: partial pressure of 
arterial carbon dioxide, PETCO2: partial pressure of end-tidal carbon dioxide. 
(Adapted from Thomovsky EJ, Bach J. Incidence of acute lung injury in dogs receiving transfusions. Journal of 
the American Veterinary Medical Association 2014;244:170-174.) 
limited to case reports of non-cardiogenic pulmonary oedema.50-54 In 2007, the first 
veterinary-specific definition for ALI (VetALI) was established by a group of investigators 
comprised primarily of Diplomates of the American Colleges of Veterinary Internal 
Medicine and Veterinary Emergency and Critical Care, individuals active in research 
relating to ALI in veterinary medicine, and specialists in ALI research in human medicine.55 
This veterinary-specific definition has since allowed clinicians to have a common set of 
criteria to aid identification and diagnosis of ALI (Table 1).  
 
      Table 1:   Definition of Veterinary Acute Lung Injury (VetALI) 
Required criteria: must have all 4 
• Tachypnoea with increased effort that started within previous 72 hours 
• Pre-existing condition known to cause multiple organ dysfunction syndrome or primary ALI (e.g. 
Sepsis, SIRS, severe trauma, received blood transfusion, pneumonia, smoke inhalation, 
drowning) 
• Evidence arising from diagnostic imaging and/or airway fluid analysis of diffuse pulmonary 
oedema due to pulmonary capillary leak coupled with no evidence of increased pulmonary 
capillary hydrostatic pressure 
• Evidence of alveolar gas exchange dysfunction 
o PaO2/FiO2 < 300 mmHg 
o PAO2-PaO2 gradient increased in the absence of an anatomic venous-arterial shunt  
o Increased PaCO2-PETCO2 gradient 
Recommended criteria: optional additional supporting evidence 
• Neutrophil-rich fluid from airway sample collected via BAL or TTW 
• Inflammatory biomarker-rich fluid from airway sample collected via BAL or TTW 





Early experimental studies in dogs found histopathological evidence consistent 
with VetALI after transfusion of filtered stored autologous blood, where microscopic 
examination of pulmonary samples revealed perivascular haemorrhage, intraalveolar 
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oedema, haemorrhage and alveolar congestion.56-58 More recently, the incidence of 
VetALI in dogs was reported in a prospective observational study conducted in 54 dogs 
receiving blood product transfusions.59 This study documented a 3.7% incidence of VetALI 
in the study dogs, which was significantly less than the reported incidence of TRALI in a 
population of critically ill people (25%).60-62 The dogs that developed VetALI displayed 
clinical signs within 48 hours after blood product transfusion, and had underlying 
inflammatory comorbidities that were reported risk factors for VetALI (Table 1).59 This 
study showed that critically ill dogs that received a transfusion can develop VetALI within 
48 hours after transfusion, and the reported incidence was significantly less in this 
population as compared to human studies. However, as ALI and ARDS can present very 
similarly, it is also possible that these dogs developed ARDS.  
 
In people, TRALI is associated with severe morbidity, with the majority of patients 
requiring mechanical ventilation and treatment in the ICU. A nested case-control study 
evaluated short-term morbidity of 74 TRALI patients, and reported a significantly 
prolonged ICU and hospital length of stay compared to matched controls.63 Similarly, a 
recent multi-institutional study in pediatric patients reported that a significantly greater 
number of TRALI patients required mechanical ventilation, extracorporeal membrane 
oxygenation, or transfer to the ICU, compared to the cohort of all patients that received a 
transfusion.64 In addition, a longer duration of mechanical ventilation has also been 
reported in pediatric TRALI patients compared with transfusion control subjects.65 
Mortality rates of patients with TRALI range from 5.1 to 15%, with frequencies potentially 
higher in critically ill patients.41, 49, 66 Short and long term mortality was evaluated between 
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TRALI and matched control patients, and found significantly higher lengths of 
hospitalisation (43.2% vs 24.3%), and 1-year (63.6% vs 46.4%), and 2 year-mortality rates 
(74.3% vs 54.3%) in TRALI patients compared to controls.63 Similarly, pediatric patients 
who developed TRALI had a significantly higher pediatric ICU mortality than transfused 
control subjects that did not develop TRALI (76.2% vs 11.3%).65 There is currently no 
published clinical veterinary study documenting TRALI and its impact on patient 
outcomes.   
 
2.1.2.3. Acute haemolytic transfusion reactions  
Acute haemolytic transfusion reactions are a potentially fatal acute reactions that 
occurs when preformed recipient antibodies react against donor RBC antigens, causing 
activation of the complement cascade that promotes the release of pro-inflammatory 
cytokines and generating a systemic inflammatory response. Activation of the 
complement cascade results in rapid destruction of transfused RBC intravascularly within 
minutes to hours of a transfusion, or sometimes a delayed destruction occurs 3-5 days 
following transfusion.12, 13 The severity of response is directly related to the number of 
RBC destroyed. In dogs, this reaction is predominantly IgG-mediated, compared to being 
IgM-mediated in cats, and it is the development of these specific IgG and IgM antibodies 
that results in immune-mediated haemolytic anaemia. Clinical signs vary in severity, 
depending on the degree of intravascular haemolysis, and reported signs include fever, 
excessive salivation, vomiting, defecation, tachypnoea, dyspnoea, tachycardia, collapse.13, 
67, 68 Potential sequelae of intravascular haemolysis are haemoglobinuria and 
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haemoglobinemia, release of thromboplastic substances leading to disseminated 
intravascular coagulation, and release of vasoactive amines resulting hypotension, shock, 
acute kidney injury, and subsequently, death.69, 70  
In dogs, antibodies are formed against dog erythrocyte antigen 1 (DEA 1). Acute 
haemolytic reaction is rare as naturally occurring anti-erythrocytic antibodies against DEA 
1 antigen has not been positively identified.71 However, as DEA 1 is the most 
immunogenic, alloantibodies will form in DEA 1 negative recipient dogs following first 
transfusion of DEA 1 positive blood. As such, it is currently the only commonly screened 
blood type likely to cause an AHTR. Failure to screen for this blood type can result in fatal 
acute haemolytic transfusion reactions should DEA 1 negative blood recipients receive 
DEA 1 positive blood.67 Conversely, cats have naturally occurring antibodies or 
alloantibodies against the red blood cell antigen not present on their own cells. In cats, 
the predominant blood typing system is the AB system. As type B cats have strong anti-A 
antibodies compared to type A cats that have weaker anti-B antibodies, even a small 
amount of type A blood transfused to a type B recipient can result in fatal reactions. This 
means that cats must be transfused with a compatible blood type and cross-matched, or 
life-threatening AHTR will likely occur.12, 68, 72, 73 
 
2.1.3. Transfusion-triggered inflammation may be linked to blood product storage lesions  
While transfusion reactions can differ quite widely in severity, all transfusion 
reactions will impact on patient morbidity. Therefore, there is a crucial need to understand 
the inflammatory mechanisms leading to transfusion reactions. The inflammatory 
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response triggered by blood transfusions in people have been characterised by 
leukocytosis and circulating pro-inflammatory biomarkers including interleukin (IL)-1β, IL-
6, IL-8, IL-17, tumour necrosis factor-α (TNF-α), interferon-γ (IFN-γ), monocyte 
chemoattractant protein-1 (MCP-1), interferon-γ-induced protein 10 (IP-10), intracellular 
adhesion molecule-1 (ICAM-1) and C-reactive protein (CRP).6, 7, 45, 74 Transfusion of older, 
stored blood with storage lesion is a possible inflammatory trigger.  
Storage lesions are pathological changes that occur in RBCs during storage, where 
RBCs undergo morphological changes, metabolic derangements and oxidative injuries, 
resulting in decreased RBC function, viability and survival.75-77 The main factors 
contributing to the development of a storage lesion are decreasing adenosine 
triphosphate (ATP), decreasing pH, and decreasing 2,3-diphosphoglycerate (DPG) in 
stored RBC units.76, 77 To produce ATP for cellular energy, RBC undergo anaerobic 
metabolism that requires preservatives in RBC units such as glucose and adenine to help 
maintain ATP levels. As such, ATP levels decrease in concentration over time with 
storage.75 Adenine triphosphate is important in maintaining RBC membrane integrity, and 
a lack of ATP will result in irreversible RBC membrane damage, characterised by 
microvesiculation of the cell membrane.77, 78 This leads to accumulation of pro-
inflammatory microparticles during RBC storage, when they are usually removed by the 
reticuloendothelial system.76, 79, 80 In a blood bag however, the lack of a reticuloendothelial 
system inevitably leads to the accumulation of these pro-inflammatory microparticles. 
Accumulation of lactic and pyruvic acid also occurs during RBC storage, decreasing pH in 
the RBC unit. This results in degradation of 2,3-DPG, which reduces oxygen off-loading 
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from haemoglobin in the tissues of transfusion recipients, perpetuating tissue hypoxia.76, 
78, 81 In addition, leukocytes degrade during storage, and release bioactive mediators. 
These bioactive mediators include histamine, lipids, plasminogen activator inhibitor-1 
(PAI-1), microparticles, myeloperoxidase, oxygen free radicals and vascular endothelial 
growth factor (VEGF).24, 79, 82-85 Oxygen free radicals directly damage RBC membranes 
causing haemolysis, and over time results in reduced viability and function of the stored 
RBC. All of these RBC-damaging processes occur simultaneously, culminating in a 
progressive storage lesion that ultimately dictates that the maximum recommended 
lifespan of a stored RBC bag is between 35-42 days.12, 86-89 
Despite optimal handling and storage, RBC inevitably develop a storage lesion that 
amplifies over time.  Transfusion of older RBC compared to fresher RBC has been shown 
to increase biomarkers of inflammation in experimentally healthy dogs receiving 
autologous blood. One crossover study found increased inflammatory biomarkers 
including segmented neutrophils, fibrinogen and CRP, in dogs transfused 21-day old RBC, 
compared to dogs transfused fresh RBC.8 Another crossover study found significant 
elevations in a separate inflammatory biomarker, MCP-1, in dogs transfused 28-day old 
RBC, compared to dogs transfused 7-day old RBC. Similar to the other study, increased 
neutrophil concentrations were also seen in these dogs.9 Being crossover studies, there 
are less confounding covariate variables given each patient acts as their own control, 
hence increasing the robustness of the results. The results of both studies demonstrate 
that older stored RBC transfusions induce inflammation in healthy dogs, compared to 
fresh or younger RBC. Similar findings were found in a human study where 14 healthy 
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subjects were autologously transfused “fresh” (3-7 days of storage) and “older” (40-42 
days of storage) RBCs, and found significant differences in iron parameters between fresh 
and older transfusions. Transfusion of elevated concentrations of iron-rich haemoglobin 
overwhelms transferrin binding capacity, leading to an increase in circulating non-
transferring-bound iron (NTBI) in the recipient.90 The presence of circulating free NTBI has 
been reported to promote bacterial growth.91, 92 In this study, increased concentrations of 
circulating NTBI, or free iron was detected after transfusion of older RBC units and 
positively correlated with enhanced proliferation of a pathogenic strain of Escherichia coli. 
Although none of these healthy subjects developed adverse clinical events following 
transfusion of older RBCs, the findings of this study suggest that there may be potential 
for adverse infectious or inflammatory events in clinically ill patients.93 Conversely, in 28 
preterm infants that received RBC transfusions, there was no correlation between post-
transfusion pro-inflammatory cytokine levels (IL-6, IL-8, MCP-1 and TNF-α) and age of RBC 
unit transfused.94 Unexpectedly, a recent meta-analysis showed an increased risk of 
transfusion reactions in critically ill people that received fresher than older RBCs.95 It 
remains unclear why transfusion of fresher RBCs causes a higher risk of transfusion 
reactions. One possible reason is inflammation and endothelial cell injury caused by 
mitochondrial DNA released from cell-free DNA during blood filtration process. Cell-free 
DNA levels have been shown to be higher in fresher RBCs units, with mitochondrial DNA 
levels decreasing with increased storage time.96, 97 One study found a positive association 
with higher mitochondrial DNA levels and incidence of FNHTR in transfusion recipients.98  
While these studies have conflicting evidence, some have suggested that healthy 
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recipients may be at a greater risk of transfusion-triggered inflammation when transfused 
older RBC. As such, methods to help mitigate the development and progression of a 
storage lesion may help reduce post-transfusion related complications.  
Similar to stored RBC, platelets also develop storage lesions. Platelet products are 
stored at room temperature, which inevitably causes platelet storage lesions to develop 
more rapidly and increases risk for bacterial growth.99, 100  Platelet metabolism occurs 
during platelet product processing and storage, leading to cellular fragmentation and 
activation, ultimately resulting in platelet lysis, decreased function and lifespan.100-105 In 
addition, pro-inflammatory cytokines such as TNF-α, IL-6 and IL-8 that accumulate during 
storage causes platelets to activate leukocytes. When activated platelets, leukocytes and 
pro-inflammatory cytokines are transfused, it can result in immunologic transfusion 
reactions in the recipient.19, 106 While there is ample evidence that transfusion triggered-
inflammation occurs with the transfusion of platelet products in people,28, 107 there have 
been no studies specifically assessing the effect of storage time on likelihood for an 
inflammatory response to develop. Also, because platelet products are often produced 
on-demand by veterinary blood banks in Australia for immediate use, rather than 
produced to be stored due to short shelf-lives, transfusion-triggered inflammation 
secondary to platelet product storage lesions are rarely seen in dogs and cats.  
 
2.1.4. Risk of transfusion-triggered inflammation differs by blood component type  
Blood collected from a donor can be transfused to a recipient as fresh whole blood 
(FWB), or it can be stored at 4°C as stored whole blood (SWB). Alternatively, there is the 
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option to divide a bag of FWB into its components including RBC, plasma, and platelet 
concentrate. These components are then stored separately, under different conditions, 
for administration to recipients based on a patient’s individual requirement. Transfusion 
of unnecessary blood components puts a patient at increased risk of antigen exposure 
that could elicit a transfusion-triggered inflammatory response, resulting in a transfusion 
reaction. This is one reason why experts in human and veterinary medicine recommend 
component therapy over whole blood (WB) administration.86, 108, 109  
There are different risk levels for development of transfusion-triggered 
inflammation with different blood components. Storage lesions significantly affect the 
quality and composition of RBC and platelet products, and transfusion of blood products 
with a storage lesion is associated with an increased frequency of FNHTR.7, 19, 92 Plasma 
products do not develop storage lesions. However, plasma contains proteins foreign to 
the recipient that may promote antigenic stimulation and result in type I hypersensitivity 
reactions and TRALI. It appears the varying compositions within different blood products 
can lead to different inflammatory responses that result in a variety of clinical 
manifestations. While each blood component has the capacity to generate any of the 
immunologic transfusion reactions, the frequency with which reactions occur appears to 
be related to blood component transfused.  
Red blood cell units have low quantities of donor plasma. Hence, transfusion of 
RBC units reduces exposure to plasma proteins that have been associated with the 
development of TRALI, and should therefore reduce the recipient’s risk of developing 
TRALI. In dogs, a retrospective study reported 9% of transfusion recipients had signs 
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consistent with acute lung injury following RBC transfusion.18 While it is possible that 
VetALI developed following RBC transfusion, critically ill dogs have multiple risk factors to 
develop acute respiratory distress syndrome (ARDS), that has similar clinical signs to 
VetALI. Hence there is the likelihood that the lung injury was not related to the 
transfusion. In saying that, as previously described, an AHTR can occur when antibodies 
in the recipient plasma reacts against donor RBC. A delayed immunologic reaction can also 
occur following >24 hours after transfusion, usually due to an anamnestic immune 
response. A low antibody titer level is mounted following a mismatched transfusion, and 
a secondary immunologic response occurs rapidly following repeated exposure to the 
same RBC antigen, leading to RBC destruction. This is known as a delayed haemolytic 
transfusion reaction, and is characterised by an unexpected rapid decline in packed cell 
volume within 3-5 days following transfusion.13, 110 
In people, transfusions of platelet products have been shown to cause FNHTR and 
TRALI, however there are currently no studies reporting the occurrence or incidence of 
such immunologic transfusion reactions in veterinary medicine. In people, an FNHTR 
reportedly occurs in every 5-20 platelet transfusions compared to a much lower incidence 
of one every 200 RBC transfusions.111 The wide range of FNHTR observed was thought to 
be associated with leukocyte concentrations of the units, as current evidence suggests the 
inflammatory response to platelets occurs due to accumulation of leukocyte-derived pro-
inflammatory cytokines within the platelet product during storage.4, 28 In the Trial to 
Reduce Alloimmunization to Platelets (TRAP) study, 2% of thrombocytopenic patients that 
received platelet transfusions developed a severe immunologic reaction characterised by 
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an increase in body temperature of > 2°C, shaking, chills, extensive urticaria, dyspnoea, 
cyanosis or bronchospasms.107 In addition, another study demonstrated transfusion of 
plasma supernatant of stored platelet units elicited FNHTR, independent of the cellular 
portion.28 These patients developed an inflammatory response following transfusion of 
accumulated pyrogenic cytokines IL-1β and IL-6 in the plasma component of stored 
platelet units.  
Plasma transfusions are the main cause of TRALI and allergic transfusion reactions 
(ATR) in people. Plasma has been implicated as the number one blood component to 
cause TRALI, and a UK haemovigilance data reported TRALI risk per component was 6.9 
times higher for FFP than RBC.112, 113 TRALI occurs in plasma recipients with significant pre-
transfusion systemic inflammation, when anti-leukocyte antibodies or pro-inflammatory 
cytokines in the transfused plasma activate primed and marginated pulmonary 
neutrophils. These neutrophils release cytotoxic products that damage pulmonary 
endothelium and cause acute lung injury.110, 114 In dogs, the incidence of VetALI following 
RBC and plasma transfusions has been reported in one study at just 3.7%, but it was 
unclear if VetALI was caused by transfusion, or if was part of multi-organ dysfunction 
caused by other severe comorbidities.59 Allergic transfusion reactions are also commonly 
associated with FFP transfusions, and are caused by the recipient’s reaction to antigens 
within the transfused plasma. Mast cells and basophils are activated, and degranulate to 
release histamine and other vasoactive mediators. Clinical signs are often mild, with just 
the development of urticaria or erythema, however in severe cases anaphylaxis can 
result.110, 114 Removing a large proportion of the plasma component from platelet and RBC 
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products prior to transfusion substantially reduces the incidence of allergic transfusion 
reactions in recipients, demonstrating that plasma plays an essential role in the 
development of allergic transfusion reactions.115   
Fresh whole blood obviously contains all blood components, and therefore, 
administration of FWB assumingly carries the combined risk for most of the immunologic 
transfusion reactions described above for each individual blood component. Stored whole 
blood would presumably increase that combined risk, due to the development of a 
storage lesion prior to transfusion, although a meta-analysis did reveal an increased risk 
of transfusion reactions in critically ill people that received fresher than older RBCs.95 
There are no published studies that compare the incidence of transfusion reactions 
between patients transfused either the specific blood component they require or WB. 
However, there are a few studies in human trauma patients that either report incidence 
of overall transfusion reactions, or compare the incidence of transfusion reactions 
between patients receiving either WB or multiple blood components. One of these studies 
performed in a level 1 trauma center reported no transfusion reactions in 47 trauma 
patients who received SWB transfusions, stored refrigerated for up to 10 days.116 A 
retrospective analysis of 94 trauma patients who received FWB transfusions found none 
of these patients developed signs of a transfusion reaction. Possible reasons that these 
acute trauma patients did not develop signs of a transfusion reaction include minimal 
priming of the immune system and the lack of storage lesions in FWB.117 In a single-center 
clinical trial, severely injured patients were randomised to receive WB or component 
therapy (1 unit of RBC and 1 unit of plasma) to treat haemorrhagic shock. Transfusion 
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associated reactions were recorded as a secondary outcome measure, and the authors 
reported no cases of TRALI in either study group.118 While these studies fail to 
demonstrate the development of expected immunologic transfusion reactions with WB 
transfusion, the studies were likely underpowered to detect a difference in WB versus 
component therapy, as transfusion reactions were not a primary outcome measure. 
Hence, the results of these studies in regard to transfusion reactions should be interpreted 
with caution. Given immunologic transfusion reactions increase patient morbidity, and 
have the potential to be life-threatening, it would make sense to process WB and 
transfused as individual blood components based on the patient’s needs to reduce this 
risk, as per expert recommendations.13, 76, 119, 120 It is important to note that however, a 
different set of recommendations exist for the management of an acutely haemorrhaging 
trauma patient. Due to the coagulopathic nature of their bleeding exacerbated by blood 
loss, acidosis, hypothermia, consumption, fibrinolysis and dilution, current trauma 
guidelines in people recommend damage control resuscitation with the use of FWB or a 
1:1 ratio of RBC and FFP for these trauma patients.117, 121   
In summary, when transfusion-triggered inflammation is severe enough to bring 
about a transfusion reaction, patients suffer from increased morbidity at a minimum, and 
in the worst cases, they die. Recommendations have been made by experts in the field of 
transfusion medicine regarding blood processing, storage, and transfusion techniques, 
which are constructed to help decrease the degree of inflammation elicited with 
transfusion administration. However, the level to which these recommendations are 
followed by veterinarians transfusing dogs and cats in Australia is uncertain. Knowing 
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current transfusion practices can help align Australian veterinary transfusion practices 
with expert recommendations, which may help alleviate transfusion-related 
complications.  
 
2.2. Blood transfusions in Australian small animal veterinary medicine  
As veterinary medicine worldwide continues to advance, more sophisticated 
medical and surgical procedures previously not attempted, can now be performed. The 
veterinary specialty of emergency and critical care medicine specifically, is working toward 
developing alignment with protocols and techniques used in human medicine, with a core 
area of development focused on transfusion medicine. While historically, veterinary 
transfusion practice consisted primarily of fresh whole blood transfusions when donors 
were available, the more recent demand for an advanced level of veterinary care for small 
animal patients has led to a requirement for blood products to be perpetually available to 
administer on-demand. Globally, the solution has been to establish both regional 
commercial and in-hospital blood banks to collect, process, and store a variety of blood 
products according to expert recommendations to ensure ready access to consistently 
high-quality products. In Australia, however, there is extremely limited commercial 
availability of blood products. Also, we expect that the expense of state-of-the-art blood 
banking equipment would limit establishment of in-hospital blood banks to large private 
and academic referral specialty hospitals, and some large 24-hour emergency hospitals. 
Therefore, in smaller practices where the infrequent need for blood products would 
preclude the cost of keeping blood on-hand, it is postulated that sourcing blood products 
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when required is likely challenging. Also, in the absence of high-quality blood processing 
equipment and standard operating procedures that are used in established in-hospital 
and commercial blood banks, quality of blood products may be substandard. There is no 
surveillance program in Australia to determine how small animal practitioners here source 
blood products, nor how transfusion practices in general align to expert 
recommendations. Below is a summary of potential sources of blood products to which 
Australian small animal practitioners may turn to when patients require transfusions. 
Following this is an outline of current recommendations around transfusion practices, 
pieced together by experts in the field of transfusion medicine, and a summary of the 
limited evidence of how actual transfusion practice globally aligns to expert 
recommendations. 
 
2.2.1. Sources of canine and feline blood  
As mentioned above, for veterinary hospitals without in-house blood banks 
stocked with blood products from community and/or terminal donors, canine and feline 
blood products are likely difficult to source in Australia. Some practices may obtain blood 
on an as-needed basis from healthy dogs and cats kept permanently in the hospital to be 
used solely as blood donors. Other intermittent sources of canine and feline blood may 
include pets of hospital staff members, or other pets owned by the same person whose 
animal requires a transfusion. Although the supply of commercially available blood 
products in Australia is limited, hospitals may purchase some to keep on hand when 
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required. Finally, hospitals may have the option to refer a patient to a hospital that can 
provide a blood transfusion when required.  
 
2.2.1.1. In-house blood bank 
Establishing a successful blood banking operation requires significant time and 
financial investments. In general, blood bank managers use expert recommendations to 
generate standard operating procedures and quality control measures to ensure high 
quality blood products with consistent quality are generated. Blood bank managers must 
recruit and screen potential blood donors to amass a group from which blood is collected 
on a routine basis. The number of donors required to maintain inventory is determined 
based on the frequency with which blood can safely be collected and the demand for 
those blood products, with additional planning for intermittent emergent demands and 
recognition of the relatively short shelf-life for some blood products. Health-screening 
potential donors can be costly, with blood testing including haematology, biochemistry, 
blood typing, and testing for relevant blood-borne pathogens. Blood bank technicians 
then set up blood donor appointments to collect blood and process those units of whole 
blood into components, using blood banking equipment including multi-bag blood 
collection systems, a refrigerated centrifuge large enough to house standardised 500-600 
mL blood bags, a plasma extractor, a tube sealer, and a line stripper.88, 122 While significant 
time and finances are invested in running a blood bank program, given that there would 
be standard operating procedures in place, the quality of blood products generated would 
likely adhere to expert recommendations.  
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2.2.1.1.1. Community blood donors  
A blood donor program would rely heavily on community canine and feline blood 
donors to maintain inventory. Typically, a blood bank coordinator maintains a blood donor 
registry that facilitates scheduled collections for the canine and feline community blood 
donors.  On-call donors may also be on the registry should there be a need for fresh blood 
products. The majority of volunteer community donors are domestic pets. Other 
examples of community donors include dogs and cats from breeders, rescue organizations 
like shelters and kennel club members.  
 
2.2.1.1.2. Terminal canine blood donors  
Greyhound racing is a popular betting sport in Australia. To this end, the racing 
industry has been an impetus for prolific greyhound breeding. Historically, greyhounds 
that failed to train well or failed early racing trials were euthanised to make room for new 
greyhound litters. Here in Western Australia, while advocating for a significant change in 
the industry to prevent this irresponsible treatment of these animals, Murdoch University 
also attempted to increase the positive outcomes that arose from this practice of 
discarding young greyhounds. With the approval from our institutional Animal Ethics 
Committee, many trainers would donate their unwanted greyhounds to the veterinary 
school for research and teaching purposes, with the end goal of humane euthanasia. 
While there was a strong push to attempt to rehome many, there were between 300 and 
400 greyhounds being donated per year, overwhelming the capacity of foster groups to 
take them in. As such, many greyhounds were used as terminal blood donors. Happily, 
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with a recent change in the legislation around breeding greyhounds for the racing 
industry, there are significantly fewer greyhounds being bred for racing. This has led to an 
easier ability to rehome those greyhounds that are not high-performing racers, and now 
fewer than 50 greyhounds per year are donated to Murdoch University for euthanasia. 
These donated greyhounds are solely the dogs that were unable to be rehomed due to 
behavioural concerns, which are typically a demonstration of aggressive behavior toward 
people or other animals. We are uncertain if donation of ex-racing greyhounds to 
veterinary hospitals for euthanasia is still relatively common elsewhere in Australia, 
however, we believe it likely continues to be a source of blood for some veterinary 
hospitals in Australia. Finally, while terminal donations remain a source of dog blood, to 
our knowledge, there is no known practice of using donated cats for terminal blood 
donation. 
The practice of performing a terminal blood donation is not openly discussed, 
likely due to the stigma associated with it. As such, this section will describe the practice 
as it occurs at Murdoch University, recognizing that it may be performed differently at 
other veterinary hospitals. Our standard operating procedure for terminal blood donation 
has been approved by our institutional Animal Ethics Committee. Following 
premedication with 0.1mg/kg IV methadone, and induction of general anaesthesia with 
alfaxalone at 2-4mg/kg IV to effect, a short, large bore cannula is placed in the carotid or 
femoral artery after it is isolated following a sterile surgical cut-down approach. Following 
this, three to four bags of whole blood, 450 to 500 mL each, are collected, and afterwards, 
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the greyhounds are humanely euthanised with pentobarbitone IV. Their bodies are then 
kept frozen to be used in veterinary cadaver teaching laboratories within the university. 
 
2.2.1.2. Commercially purchased blood products or external referrals for transfusion  
Veterinary hospitals without a blood bank have the option to purchase some types 
of commercially prepared blood products to keep on-hand for use. The blood products 
from commercial companies are presumed to be of very high quality, as they would have 
standard operating protocols aligned with expert guidelines for collection, handling and 
processing to ensure consistency and high quality across all their end-products. There are 
just two companies selling canine blood productsa,b in Australia, and to our knowledge, 
there are no commercially available feline blood products. Canine packed RBC are often 
limited in stock, whereas FFP is more readily available for purchase from these companies. 
However, the decision to maintain this stock may be financially unjustifiable, as these 
products are expensive and some have a very limited shelf-life. Alternatively, practices 
within the same community may choose to pool their resources to maintain purchased 
blood products at a single location to maximise the likelihood of the blood product being 
used, and in turn make it more financially viable for these practices as the maintenance 
cost is shared between practices. It is important to note that more specialised blood 
component products such as platelet concentrate and cryoprecipitate are not 
commercially available in Australia. The limitations of these commercial sources may 
make veterinarians more inclined to refer patients in need of blood product transfusions, 
as the alternate option would be to collect FWB from a donor.  
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2.2.1.3. Resident donors, or pets of staff members or owners of blood recipient  
Hospitals that do not have the option to refer patients elsewhere may elect to keep 
dog and cat blood donors as housed within the hospital premises as a quick resource when 
needed emergently. Quality of life for permanent resident blood donors should be 
considered, and there may be animal welfare regulatory laws in place to ensure this 
practice is performed ethically.  
Pets of staff members are also viable options for blood sources, however 
unpredictability of staff turnover may make this option unreliable. Other pets owned by 
the same family whose animal requires a transfusion may also be an option for an 
emergent source of blood. It is important to note that there will unlikely be time to 
appropriately screen these pets thoroughly to ensure they are suitable donors. Owners 
must therefore be informed of the risk to the donor during blood collection as well as the 
risk to the recipient for transmission of blood-borne pathogens. Importantly, in all cases 
where stored blood is not readily available, collecting blood on-demand will cause a 
considerable time-delay to transfusion, and urgent stabilisation of a haemorrhaging 
patient using this method is often unrealistic.  
In situations where resident donors, pets of staff members or owners of blood 
recipient provides the source of blood to the recipient, blood transfusions presumably do 
not occur frequently in these practices. As such, it is likely that fresh whole blood would 
be administered, standard operating protocols may not be in place, expert 
recommendations of blood collection may not be followed, and may result in 
inconsistency with the quality of blood collected.     
 46 
2.2.2. Expert recommendations on veterinary blood transfusions  
While there are many published reviews by individual experts on transfusion 
medicine topics in peer-reviewed journals12, 13, 76, 119, 123 and textbooks,124-126 there is no 
comprehensive expert-led evidence-based consensus statement to help guide veterinary 
transfusion practices. While there has been a call for a comprehensive consensus 
statement aimed to promote the safety of blood recipients,119 there are currently just two 
evidence-based consensus statements focused on blood-borne pathogen screening in 
blood donors.123, 127 Promisingly, there is a current working group of experts within the 
international veterinary transfusion medicine interest group, known as the Association of 
Veterinary Hematology and Transfusion Medicine (AVHTM), who are aiming to provide 
consensus guidelines on defining transfusion reactions in veterinary medicine. Ideally, 
however, one overarching expert-led evidence-based consensus statement should be 
available in an open-access format to provide all stakeholders in veterinary transfusion 
medicine recommendations of best transfusion practices. Without this type of resource, 
it is unknown if Australian veterinarians involved with collecting, processing, storing, or 
transfusing blood are across all pertinent scientific literature available to practice 
evidence-based transfusion medicine. Potential consequences of poor adherence to 
expert recommendations include increased risk of blood donor morbidity if blood 
collection techniques are not optimised, wasting of blood products should they be 
processed or stored incorrectly, and increased blood recipient morbidity and mortality 
due to increased transfusion-related complications with improper collection, processing, 
storage, or administration of blood products. 
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Some current evidence-based expert recommendations pieced together from 
multiple published resources include: screening blood donors for regionally-specific 
blood-borne pathogens prior to collection, storing blood products in a dedicated 
refrigerator, transfusion of blood components rather than whole blood where possible, 
compatibility testing blood recipients to the blood product prior to transfusion, 
administering refrigerated blood without first warming it to room or body temperature, 
and withholding prophylactic anti-allergy or anti-fever medications prior to transfusion.13, 
76, 119, 123 It is through these recommendations that “best practice” is inferred, which, if 
followed, should help decrease the risk for transfusion-related complications. 
 
2.2.2.1. Blood donor screening  
A thorough medical history and physical examination is first performed to evaluate 
for potential factors that may preclude an animal from becoming a blood donor. Other 
than being in good health, blood donors must have their annually assessed haematology 
and biochemistry results fall within reference intervals, and they must test negative for 
relevant infectious diseases, as defined by the 2015 ACVIM & AVHTM updated consensus 
statement on screening feline and canine blood donors for blood borne pathogens.12, 13, 
119, 127 The guidelines recommend screening potential blood donors for infectious diseases 
considered relevant based on their geographical location, propensity to be transmissible 
and cause significant morbidity in recipients, and availability and reliability of tests. In 
Australia, several vector-borne diseases endemic in other countries such as, ehrlichiosis, 
leishmaniasis, trypanosomiasis and neorickettsiosis are exotic or rarely reported, and 
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hence are generally not tested for in canine blood donors. While uncommon, Mycoplasma 
haemocanis and a non-vector borne disease Brucella canis are present in Australia, and 
experts recommend testing for both, where possible. Most recently, few cases of 
Ehrlichiosis were reported in the north and west of Australia, and testing should be 
considered in these regions if the disease becomes endemic. For potential feline blood 
donors, the most commonly tested infectious diseases are non-vector pathogens feline 
leukemia virus (FeLV) and feline immunodeficiency virus (FIV). Other less commonly 
tested vector-borne pathogens in cats include anaplasmosis, bartonellosis and 
mycoplasmosis.127 The risk of forgoing screening of potential blood donors would be 
pathogen transmission to the transfused recipient leading to active infection.  
 
2.2.2.2. Blood component therapy over whole blood transfusion 
It is considered “best practice” to transfuse blood components rather than whole 
blood based on recommendations by experts in veterinary transfusion medicine for 
several reasons.12, 86, 88, 108 Firstly, only the required blood component is transfused to the 
patient, thereby increasing the capacity of one unit of whole blood to treat multiple 
critically ill patients. This maximises the utility of each whole blood unit, and also improves 
cost efficiency. Secondly, as only a fraction of a whole blood unit is administered, the 
administration of a smaller overall volume is considered safer for patients at risk of fluid 
overload, including those with cardiac disease, or oliguric or anuric kidney disease. Finally, 
administering only the required fraction of a whole blood unit may reduce the risk of 
transfusion-relation complications by preventing exposure to unnecessary blood 
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components that may potentiate an allergic or pro-inflammatory reaction.29, 67, 79, 82, 86, 122, 
128, 129 Given these benefits, all attempts should be made to source and transfuse blood 
components rather than whole blood.    
 
2.2.2.3. Storage of whole blood and packed red blood cells  
Appropriate storage of RBC-containing products is vital to optimise retention of its 
quality. The use of a dedicated blood product refrigerator has been recommended to 
minimise temperature fluctuations, as accidental freezing or over-warming of red blood 
cell products can cause haemolysis, and result in transfusion reactions.87 To maintain a 
constant temperature between 1 and 6°C, and prevent fluctuations, refrigerators should 
be opened as infrequently as possible.12, 86-89 To assess for temperature fluctuations, 
continuous temperature monitoring should be instituted either using a device with an 
alarm, or a reliable thermometer placed inside the refrigerator.  
There are different recommendations for storing many different blood 
components. As per expert recommendations, the maximum length of storage time for 
packed RBCs in RBC preservative AS-3 or SAGM is 35-37 days. In contrast, as platelets have 
a short lifespan, platelet concentrates can be stored for a maximum of 5 days with 
constant agitation at 22°C, while fresh frozen plasma can be stored for a maximum of 1 
year in the freezer maintained at -20 to -30°C.12, 88 This section of the literature review will 
primarily focus on RBC products.   
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2.2.2.4. Blood typing and cross-matching 
Experts recommend administering type-specific blood to which the recipient has 
been cross-matched, to avoid acute haemolytic transfusion reactions.12, 13, 76, 86, 119, 123 A 
review article in 2009 outlined an evidence-based need for appropriate pre-transfusion 
screening in veterinary medicine, and recommended standardising pre-transfusion testing 
in transfusion recipients.119 More recently, a review article provided an update on pre-
transfusion serological testing in dogs and cats.70 Transfusion naïve dogs do not have 
circulating isoantibodies against foreign antigens from donor blood, hence it is considered 
acceptable to transfuse first without blood typing in an emergency situation. Unlike dogs, 
cats have strong preformed antibodies against the antigen they lack, and as such, must 
always be blood typed and cross-matched prior to each transfusion.12, 72, 73    
Cross-matching serologically tests for donor RBC and recipient compatibility. In 
recent years, discovery of new blood types in dogs and cats have prompted veterinary 
transfusion experts to strongly recommend cross-matching dogs and cats prior to a 
transfusion as it can identify serological incompatibilities separate from tested blood 
types.12, 67, 122 For example, a new dog erythrocyte antigen, later termed “Dal”, was 
discovered when a previously transfused Dalmatian that was Dal-negative developed anti-
Dal antibodies following transfusion, and had incompatible cross-matches to multiple 
donors thereafter.130 Dalmatians and other breeds lacking the Dal antigen are thus at risk 
of fatal haemolytic transfusion reactions if they receive a second transfusion of Dal 
positive blood, following sensitisation. In addition, two new blood groups, Kai 1 and Kai 2 
were also recently identified in dogs, and may cause development of anti-Kai 1 and anti-
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Kai 2 alloantibodies, and subsequently haemolytic reactions if Kai-mismatched 
transfusions are performed.131 The frequency and prevalence of these new antigens in 
dog breeds universally remain unclear. Additionally, as these blood types are not routinely 
available to be tested bedside, it further highlights the importance of cross-matching prior 
to a transfusion.  
Similarly in cats, the recent discovery of the Mik RBC antigen has further 
emphasised the clinical relevance of cross-matching prior to transfusion, as the presence 
of naturally occurring anti-Mik antibodies can result in an acute haemolytic transfusion 
reaction if Mik-positive blood is transfused to a Mik-negative recipient.73 Given blood 
typing in cats will only detect the A and B RBC antigens, cross-matching is the only way to 
prevent Mik-related acute haemolytic transfusion reactions. Additionally, a recent study 
reported that cats transfused type-specific blood to which they had been cross-matched 
had a larger increase in post-transfusion PCV, compared to those that were not cross-
matched.132 Given the potential risk of transfusing incompatible RBC which could lead to 
an acute haemolytic transfusion reaction, blood typing and, ideally, cross-matching, 
should be performed prior to transfusion in both dogs and cats.12, 13, 72, 119 It is important 
to note, however, that while compatibility testing will help prevent fatal acute haemolytic 




2.2.2.5. Premedication prior to transfusions 
The prophylactic administration of pre-transfusion medications aimed at reducing 
a transfusion recipient’s risk of allergic transfusion reaction and FNHTR is a deeply-
established medical practice based on historical habits, but not on evidence of their 
efficacy. To date, this practice, also known as premedication, is still frequently performed 
by physicians transfusing people, as evidenced in 2 recent surveys. The first surveyed 
Japanese medical practitioners and reported that 21.1% of respondents premedicate their 
patients prior to blood product transfusions.133 The second surveyed Canadian 
paediatricians and found 87% of their respondents premedicate their patients in up to 
50% of RBC transfusions.134  
While allergic reactions can develop following blood product transfusions, the 
current evidence on the benefits of pre-medication remains weak in people135-141 and 
dogs.142 A randomised, blinded clinical trial evaluated the efficacy of an acetaminophen 
and diphenhydramine combination as premedication prior to platelet transfusions in 
oncology patients, and found no significant difference in incidence of FNHTR in treatment 
versus placebo group.140 A similarly designed study performed in haematology and 
oncology patients that received either an acetaminophen and diphenhydramine 
combination or placebo as premedication prior to RBC or platelet transfusions reported 
similar findings, where there was no significant difference in the incidence of FNHTR 
between groups.135 These results are consistent with a recently published meta-analysis 
that also found no benefit of premedicating with acetaminophen and diphenhydramine 
prior to transfusion.141 Likewise in dogs, a retrospective study evaluated 558 dogs that 
 53 
received 935 transfusions and reported that the overall transfusion reaction occurrence 
did not significantly decrease when patients were premedicated with corticosteroids 
and/or antihistamines.142 Overall, given the lack of benefit in reducing transfusion 
reactions, coupled with potential risks associated with administering immunomodulatory 
drugs, experts in the field of veterinary transfusion medicine recommend against 
premedication prior to transfusions.  
 
2.2.3. Current veterinary blood banking and transfusion practices 
The veterinary literature surrounding current veterinary blood banking and 
transfusion practices remains very limited. In the absence of an open-access international 
guidelines to inform of ideal transfusion practices, it is possible that transfusion practices 
are not aligned with expert recommendations. Consequentially, transfusions that are 
performed differently may increase risk of transfusion-associated complications. This 
section provides a description on current global transfusion practice based on the limited 
published evidence available.  
 
2.2.3.1. In-hospital blood banking 
Being a time-intensive and expensive endeavour, once an uncommon practice a 
few decades ago, blood banking is now more commonly performed in veterinary practices 
globally. A survey published in 1992 surveyed 25 small-animal general practices in the US, 
and found that 48% of practices obtained blood from “borrowed dogs”, 48% from dogs 
kept in-hospital as donors, and 4% from a regional veterinary school.143 In contrast, a 
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survey conducted in 2012 that included 73 specialty hospitals from the US, Canada, the 
UK, Switzerland, and Australia revealed approximately 50% of hospitals used a 
combination of in-house blood banks and commercially purchased blood products to 
provide canine blood products, and 19% of hospitals used solely in-house blood banks to 
provide canine blood products. A large proportion (85%) of these hospitals reported 
routinely using dogs owned by staff members, 53% used client-owned dogs, and only 11% 
used dogs kept in-hospital as blood donors.144 This change to purchasing blood products 
from commercial sources and using established in-hospital blood banks compared to 
using “borrowed” and clinic dogs as sources of blood products is likely multifactorial. 
Development of commercial blood banks to extend the limited resource and increase 
availability of blood products for sale, improved knowledge of transfusion medicine, and 
potentially stricter enforcement of regulatory laws on keeping permanently housed clinic 
donors are all possible reasons for this change. While the type of practices surveyed in 
both studies were different, the dramatic shift in practice helped illuminate current blood 
banking and transfusion practices in specialty hospitals.  
Due to the costs of establishing and maintaining a blood bank, it is assumed that 
only large specialty referral or emergency hospitals with high caseloads would be likely to 
have financial justification to have an in-house blood bank. As previously described, blood 
banking incurs a significant cost to the hospital. In addition to equipment and staffing 
costs, costs are incurred when health-screening potential donors, and many donation 
programs will provide incentives to their donors which also contributes to the cost of 
running a blood bank. Money is lost if inventory reaches the end of its shelf life before 
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use.12, 88, 145 Therefore, due to increasing demand for financially viable sources of canine 
and feline blood products, we expect there will be a push toward establishing regional 
commercial blood banks in Australia, similar to those developed in the US.c  
 
2.2.3.2. Commercial sources of blood products  
Commercial blood banking services for dogs and cats can be broadly categorised 
into local, regional, and national services. In the US and Europe, there are large 
commercial blood banks that have the ability to sell blood products nationally to all 
veterinary practices. Examples include the Animal Blood Resources and Veterinarians’ 
Blood Bank in the US, Pet Blood Bank in the UK and Canadian Animal Blood Bank in 
Canada. Most commercial blood banks are limited to selling high-demand products with 
longer shelf-lives, including canine and feline packed RBC and FFP. Specialised blood 
products including platelets and cryoprecipitate are typically not available. In Australia, 
only onea of the two companies selling dog blood products can ship canine FFP 
nationwide. Shipping constraints require canine packed RBCs to only be available 
regionally in Australia, where the blood banks are based. There are currently no 
commercially available feline blood products in Australia or Europe. Given the expense 
required to run a blood bank, it is not known if a hospital generates large amounts of 
revenue from it. In saying that, there are also considerable finances put into purchasing 
commercial products, storing them, and money is lost if the blood products expire before 
use. Regardless, one huge advantage of an in-hospital blood bank is that it undeniably 
provides a high standard of care in veterinary transfusion medicine as per expert 
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recommendations to perform blood component transfusions, and there is evidence of this 
growing practice in specialty hospitals.144 Unfortunately, the limited availability of 
commercial blood products in some parts of the world has continued to make it 
challenging for veterinarians without an in-hospital blood bank to provide blood 
component transfusions for their patients. Given the paucity of commercially available 
products in Australia, we presume most veterinary clinics would not be able to rely on this 
as a source, and postulate that many Australian veterinarians must obtain dog and cat 
blood from alternative sources as described above.  
 
2.2.3.3. Storage of whole blood and packed red blood cells 
Blood bags must be stored within a stable 1-6°C temperature range to maintain 
red cell viability. Erythrocyte membrane damage can occur with significant blood 
temperature fluctuations, leading to in vitro or in vivo (post-transfusion) haemolysis. 
Acute in vivo haemolysis can induce a fulminant systemic inflammatory response that will 
increase the risk of multiple organ dysfunction and death in the recipient. A recent case 
report details this process in 4 dogs that developed signs of an acute haemolytic 
transfusion reaction following transfusion of red cell products that were inappropriately 
stored in an all-purpose refrigerator rather than a temperature-controlled laboratory 
refrigerator dedicated to RBC storage.146 There are no studies evaluating the effect of 
fluctuations in refrigerator temperatures on canine and feline post-transfusion RBC 
viability during storage. However, in vitro studies on human RBC found lysis occurs due to 
significant irreversible changes to the structure of erythrocyte membranes when they are 
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exposed to temperatures above 40°C, or undergo freeze-thaw cycling.87 Veterinary expert 
recommendations on blood refrigerator temperatures for storage of RBC bags are thus 
extrapolated from human literature, and they have provided veterinarians with a better 
understanding of the potential impact of incorrect storage temperatures of canine and 
feline blood products. 
 
2.2.3.4. Blood donor screening and pre-transfusion testing 
Advances in veterinary blood donor screening and pre-transfusion compatibility 
testing in recent years are illustrated by the results of the two surveys previously 
described.143, 144 In small animal practices surveyed in 1992, 36% did not screen dogs for 
infectious diseases or perform routine haematology prior to donation. Blood typing was 
performed in only 32% of canine donors, and was not routinely performed in recipients. 
Only 1 practice performed crossmatches for all canine transfusion cases.36 Conversely, in 
the 2012 survey of specialty hospitals, 95% of hospitals performed routine screening for 
blood-borne pathogens in canine and feline blood donors, and 96% of respondents blood 
typed or cross-matched dogs and cats prior to blood product transfusions.144 
Improvements in transfusion practices are likely attributed to increased awareness of the 
risk of infectious disease transmission and potentially fatal consequences of poor blood 
compatibility between donor and recipient, as well as the increased availability of in-
house pre-transfusion compatibility testing kits. Blood typing and cross-matching kits 
have long shelf-lives, are affordable, easy to use, and are available for purchase globally. 
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Therefore, we postulate that blood donor screening and pre-transfusion testing is 
routinely performed by Australian veterinarians who transfuse dogs and cats.  
 
2.2.3.5. Premedication prior to transfusion 
As detailed above, administration of prophylactic medications to prevent 
transfusion reactions in blood recipients is not recommended based on the lack of 
benefits in several randomised clinical trials in people.135-141 It is unclear how commonly 
this practice is performed in Australian veterinary patients, but the 2012 survey of 
primarily American private specialty and academic referral hospitals reported only 8% of 
respondents routinely administer diphenhydramine to their patients prior to all blood 
transfusions.144 As a recent study in dogs revealed administration of diphenhydramine 
prior to transfusion may decrease the likelihood of an allergic reaction, future studies are 
warranted to determine if a true benefit of premedication exists in veterinary patients.142 
As described in the previous section, allergic transfusion reactions are usually not life-
threatening, unless anaphylaxis develops. However, significant discomfort can occur in 
recipients despite mild clinical signs of urticaria, angioedema, pruritis and erythema. In 
addition, as these minor reactions are similar to signs of other transfusion reactions, it 
further increases patient morbidity as transfusions may have to be halted or discontinued 
for further investigations, subsequently resulting in prolonged hospital stays for 
recipients.13, 110, 115, 147  
In summary, there is current work towards advancing veterinary transfusion 
medicine by developing protocols and techniques used in human medicine. Veterinary 
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transfusion medicine experts recognised the need for sources of high-quality blood 
products and have made recommendations in regard to collection, processing and 
storage.  As previously discussed, during storage, undesirable bioactive mediators like 
storage lesions and pro-inflammatory cytokines accumulate in blood products over 
time,24, 75-77, 79, 82-85 and transfusion of older blood products can cause transfusion-related 
complications in people148, 149 and dogs.150 As such, if transfusion practices are not aligned 
to expert recommendations, these post-transfusion-related complications may be 
exacerbated, which may increase patient morbidity and mortality. It currently remains 
unclear if transfusion practices in Australia are aligned with expert recommendations, 
based on the limited published evidence. Without a single open-access international 
consensus statement to guide practitioners, we presume there would be significant 
differences in current transfusion practices compared to expert recommendations. The 
outcome of poor transfusion practices in recipients include increased patient morbidity 
and mortality, with increased likelihood of transfusion-triggered inflammatory reactions, 
particularly if incorrectly processed blood products are transfused. There are currently 
veterinary blood banking techniques such as leukoreduction, which may further decrease 
transfusion-related adverse reactions, even if blood collection, processing and storage has 
been performed as per expert recommendations. On top of many existing researches 
performed on leukoreduction in human transfusion medicine, there is already early 
research investigating the benefits of leukoreduction in canine blood products, with 
encouraging results to potentially decrease transfusion recipient morbidity/mortality. 
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2.3. Leukoreduction, a blood processing technique in veterinary medicine 
One major area of interest in transfusion medicine in recent years is exploring the 
use of a veterinary blood banking technique called leukoreduction, to help reduce 
transfusion-related adverse reactions in people and dogs, with the ultimate goal of 
decreasing transfusion recipient morbidity and mortality. 
This section describes details on leukoreduction, including the different methods 
available, the logistics involved, and the types and efficacies of leukoreduction filters. 
Specifically, two logistically different methods of leukoreduction using filtration will be 
described. Finally, a summary of the use of leukoreduction in human, canine, and feline 
blood products will be discussed.  
 
2.3.1. Definitions: Leukoreduction, leukodepletion, and buffy-coat poor  
There are multiple terms used to describe the removal of some portion of the 
leukocytes and platelets present within RBC bags. The terms leukodepletion and 
leukoreduction are frequently used interchangeably, though there are differences 
between the two. Strictly-speaking, leukoreduction is performed by separating and 
removing the buffy coat from RBC during blood processing. The buffy coat contains 
leukocytes and platelets, which are cellular components with a lower specific gravity than 
RBC. This layer of cells can be identified as a thin, cream-coloured layer just above the RBC 
after whole blood is centrifuged. Leukoreduced blood is also known as buffy-coat poor 
blood, and it contains no more than 1 x 108 white blood cells/bag. Leukodepletion, on the 
other hand, is performed with a specially-designed filter that is significantly more efficient 
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at leukocyte removal than leukoreduction. It contains at least 100-fold fewer leukocytes 
than leukoreduced blood, with acceptable residual leukocyte concentrations of no more 
than < 1 x 106 white blood cells/bag.151, 152  
Despite the differences between the two definitions, there is a convention in 
veterinary medicine that leukoreduction is used more frequently to describe products 
that have actually been leukodepleted.8, 9, 20-22 Given this convention, throughout this 
thesis, I have elected to use the term “leukoreduction” and “leukoreduced” (LR) to 
describe products that would fit the strict definition of leukodepleted, and the term 
“buffy-coat-poor” (BCP) to describe products that would fit the strict definition of 
leukoreduced. 
 
2.3.2.  Methods and logistics  
Various blood processing techniques have been described to remove leukocytes 
from human RBC units. These methods include collection of RBCs using apheresis, buffy 
coat removal after sedimentation or centrifugation of a conventionally collected whole 
blood bags, freezing and thawing cryoprotected RBC bags, and filtration of RBC bags.145, 
153, 154  
Apheresis is a blood collection technique that permits collection of specific blood 
components at a pre-determined volume, while all other blood components are given 
back to the donor. Blood from the donor is anticoagulated as it enters an extracorporeal 
circuit. Centrifugation applied to this circuit separates blood components according to 
specific gravity, with RBC concentrate representing the densest layer. Diversion of this RBC 
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layer into a collection bag provides a BCP RBC product, however post-apheresis filtration 
will be required to achieve complete leukoreduction.145, 155 The remaining less dense 
blood components including most white blood cells, platelets, and plasma are returned 
to the donor. One advantage of the apheresis method for creating BCP RBC units is better 
inventory control, as only the required blood components are created from any particular 
donor. This can include RBC alone or a combination of blood components, such as RBC 
and platelets, or RBC and plasma. There is also improved quality control of the blood 
components produced, as the blood component separation is performed by the apheresis 
machine at the time of collection, eliminating product processing errors or 
misidentification of units. Disadvantages of this method include increased risk for donor 
complications, longer collection time, costly equipment and consumables, and the 
requirement for highly skilled operators.156, 157 
Other uncommon techniques by which BCP RBCs may be produced are through 
manual removal of the buffy coat following centrifugation or sedimentation of a RBC unit, 
or by a freeze-thaw method. Similar to the apheresis method, buffy coat removal 
following centrifugation or sedimentation is only able to remove 70-90% of white blood 
cells. While a second centrifugation or sedimentation step can be performed to reduce 
white blood cell concentrations further, this leads to a significant loss of RBCs. In addition, 
similar to apheresis, the sedimentation procedure is time and labour intensive.153 The 
freeze-thaw method effectively destroys leukocytes when the blood unit is frozen 
following the addition of a cryoprotective agent. However, the expense required to 
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maintain a facility to freeze and store the blood products has caused this method to fall 
out of favour.153  
The most common way by which RBC are leukoreduced is through the filtration 
method. Its many advantages over the techniques described above have made it the 
universally accepted LR technique in blood banks globally.152, 158 White blood cells are 
removed from either BCP or whole blood units when blood moves via gravity flow through 
the LR filter into an integrally attached storage bag. Leukocytes are trapped within the 
filter and are discarded. This method is advantageous for several reasons. First, leukocyte 
filters are incorporated into the closed collection system, which ensures the method can 
be performed without risk of bacterial contamination. Second, this technique is less time 
consuming than the methods described above. Finally, the blood collection systems with 
incorporated LR filters are relatively inexpensive and require no special equipment or 
trained technicians to operate.153 While there are important benefits to leukoreduction 
using filtration, there are also some limitations. Firstly, LR filters increase the total cost of 
each blood collection system, though this cost is becoming negligible as more companies 
are producing systems with LR filters. Secondly, the filtration process adds additional 
processing time of 15-20 minutes per blood bag.159, 160 Finally, every RBC unit will 
experience an average RBC loss of 10-12%, due to volume being trapped within the filter 
following the procedure.159, 160 As these limitations are relatively minor compared with 
those of the other techniques, leukoreduction by filtration still holds up as the optimal 
method by which leukocytes can be removed from blood products.  
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2.3.2.1. Leukoreduction filters 
Human hospitals adopt guidelines either from the American Association of Blood 
Banks (AABB)152 or The European Council161 as their accepted standards for leukoreduced 
blood products, where following LR, the leukocyte content should be <5 x 106 or <1 x 106 
per bag of blood, respectively. This translates to a minimum of 99.9% reduction. The AABB 
adopted their standards from the Food and Drug Administration’s (FDA) guidelines on pre-
storage leukocyte reduction of whole blood and blood components intended for 
transfusion.162 While it is not clearly stated, it appears that the AABB’s recommendations 
for the leukocyte count to be <5 x 106 per unit of blood following leukoreduction was 
based on evidence that this prevented transmission of cytomegalovirus (CMV) in 
people.163, 164 
Leukoreduction filters are now mainly made of cellulose acetate fibres.153 The 
earlier generation filters were often made of cotton wool or nylon material with the 
purpose of removing large clots, foreign material and microaggregates. Unfortunately, 
these earlier generation filters were unable to remove the majority of leukocytes as the 
sieve size was not fine enough to remove individual leukocytes if they did not aggregate 
together. The newer generation filters retain leukocytes via adsorption during filtration. 
Currently, third and fourth generation synthetic fibre filters are being used specifically for 
blood product leukoreduction.165 Recently, a new blood filter developed is reported to 
remove 99.9999% of leukocytes.166 
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2.3.2.2. Timing of leukoreduction via filtration 
Leukoreduction using the filtration method can be performed pre-storage, where 
white blood cells are removed immediately after blood collection, or post-storage, where 
white blood cells are removed right before the blood is administered to a patient. 
 
2.3.2.2.1. Pre-storage filtration 
Leukoreduction performed during or just after blood collection is universally 
preferred. In both human and canine stored RBC, pre-storage LR has been shown to 
attenuate some components of the storage lesion, including accumulation of 
inflammatory microparticles,79, 167 VEGF82 and pro-inflammatory cytokines including IL-1β, 
IL-8, TNF- α, and IL-6.5, 20, 22, 26, 29, 168 In people, pre-storage LR has been shown to 
significantly reduce the incidence of FNHTR.14, 27, 169-171 In healthy dogs, pre-storage LR has 
been shown to decrease markers of inflammation post-transfusion.8 For these reasons, 
pre-storage filtration is the preferred leukoreduction technique. 
 
2.3.2.2.2. Post-storage filtration 
Now that many blood banks have adopted universal pre-storage LR, post-storage 
LR is very uncommonly performed. While it is overall a less expensive method, as filter 
use is limited to transfused blood units rather than all processed blood units, there are 
many reasons post-storage filtration has fallen out of favour. Firstly, while post-storage LR 
has been reported to be as effective as pre-storage LR in the removal of leukocytes,172 it 
is more difficult to perform quality control of these components to ensure the final 
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leukocyte concentration is within the standards recommended by the AABB or European 
Council because LR is performed during the transfusion. Secondly, as the LR filter limits 
the maximum flow rate, post-storage LR is not a viable option for haemorrhaging patients 
requiring rapid transfusions.173 Thirdly, post-storage LR does not prevent cytokine 
accumulation in blood products,174 nor decrease the incidence of FNHTR in patients, 
compared with pre-storage LR.175  
 
2.3.2.3.  Efficacy of leukoreduction in human and canine blood products  
Leukoreduction filters are reported to remove between 99.9% and 99.999% of 
leukocytes per human blood bag, with newer generation filters being most effective.176-
178 Regardless, all commercially available filters meet the standard guidelines of AABB and 
The European Council.  
 While LR is not a blood processing technique universally used in veterinary 
medicine, there are several studies on the efficacy of LR filters in canine blood. Similar to 
human blood, LR filters have been shown to remove 99.9% of leukocytes from canine 
whole blood.8, 20, 22, 179, 180  
 
2.3.2.4. Leukoreduction of feline blood products  
Leukoreduction is not routinely performed in feline blood due to significant waste 
to the filter.181 Approximately 10-12% of blood product volume is lost when it is retained 
within a typical leukoreduction filter during the filtration process,159, 160 and the total 
volume of the whole blood product collect from a feline blood donor is just 60 mL. 
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However, in a 2012 pilot study, eight 60 mL fresh whole blood bags from healthy donor 
cats were leukoreduced using a human neonatal leukoreduction filter, with a residual 
volume of just 8 mL.181 When filtration was performed on bags of blood that had been 
chilled at 4°C for 1 hour, the leukoreduction achieved using this filter was reportedly 100%. 
However, as the lower limit of detection of leukocytes by the haematology machine used 
in this study is 500 cells/µL, there may have been an unacceptable level of leukocytes 
remaining in the 52 mL bag of leukoreduced blood (up to 2.6 x 107 cells/bag.)181 
Additionally, while the loss of 13% (8/60 mL) of the total blood bag volume to a neonatal 
leukoreduction filter is of a similar proportion to the canine RBC volume lost to a standard 
leukoreduction filter, cat blood is arguably more precious on a mL to mL comparison with 
dog blood, mainly due to donor-related challenges. Collecting cat blood is riskier to the 
donors than in canine blood banking, as cats must be heavily sedated to collect a full blood 
bag. Cats tend to be more susceptible to kidney injury with blood loss from donation, 
coupled with low blood pressure that could be induced with heavy sedation.182, 183 To 
mitigate risk to the cat donors, blood banks tend to collect the fewest bags necessary to 
maintain inventory at the barest minimum. With so few bags in supply at any given time, 
completely full bags are needed to ensure cat recipients will receive the maximum amount 
of RBC as possible, as there are so few bags available. This is particularly true of the rarer 
types of blood, B and AB, where obtaining additional bags on an as needed basis may be 
impossible. Finally, a comparable filter to the one likely used in this pilot study was priced 
to cost around $13.75 USD,d and it is unclear if leukoreduction would be worth the cost of 
the filter and the volume of blood lost to it during filtration. Studies assessing the effects 
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of LR on the storage lesion and on clinical outcome in veterinary transfusion recipients will 
be required to first understand potential benefits.  
To summarise, while there are many methods to achieve leukoreduction, the pre-
storage filtration method is currently universally accepted. With newer generation LR 
filters, > 99.9% of leukocytes are able to be removed from human, canine and feline blood. 
With LR, 10-12% of blood is lost through the filter during the filtration process, and is 
typically not considered a significant loss in human and dog blood bags. However, it 
remains a limitation for feline blood bags to be leukoreduced given the paucity of feline 
RBC bags available in blood banks at any given time. In people, leukocytes within RBC units 
have been associated with immunologic transfusion reactions such as FNHTR. As such, 
transfusing LR RBC has been shown to decrease incidences of transfusion reactions, and 
in turn reducing morbidity and mortality in transfusion recipients.  
 
2.4. Effect of leukoreduction on morbidity and mortality in transfusion recipients 
Transfusion-related complications result in increased morbidity and mortality in 
recipients. In people, leukoreduction of RBC prior to transfusion is one method used to 
reduce the incidences of transfusion-related complications, with many studies 
investigating primary and secondary outcome measures to determine if a true benefit 
exists, such that implementation of universal leukoreduction should be mandated. This 
section describes the effect of leukoreduction on incidence of FNHTR, post-operative 
infections, length of hospitalisation, multi-organ dysfunction syndrome and mortality in 
people. The effect of leukoreduction in pre-clinical and clinical canine transfusion 
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recipients will also be explored. Lastly, the implementation of universal leukoreduction in 
human and veterinary blood banks will be discussed.   
 
2.4.1. Implementation of leukoreduction decreases incidence of FNHTR in people 
As explained earlier, transfusion of blood products rich with pro-inflammatory 
cytokines is one mechanism by which FNHTR occurs.3, 4, 15, 184 Several studies have shown 
that pro-inflammatory cytokines including IL-1β, IL-6, IL-8, and TNF-α accumulate during 
storage, with highest concentrations present in the oldest blood products. When these 
blood products are leukoreduced prior to storage however, accumulation of pro-
inflammatory cytokines is prevented.5, 26, 175, 185 Furthermore, transfusing cytokine-poor 
leukoreduced blood products rather than cytokine-rich non-leukoreduced  blood products 
decreases the incidence of FNHTR in transfusion recipients.1, 2, 14, 27, 169, 171 In already 
clinically unwell recipients, helping to reduce incidences of FNHTR may help reduce 
further patient morbidity.  
 
2.4.2. Effect of leukoreduction on post-operative infections in people receiving transfusions 
Administration of both pre-storage and post-storage leukoreduced blood products 
instead of non-leukoreduced (NLR) or BCP blood products have been shown to decrease 
post-operative infections in some transfusion recipients, however the literature remains 
divided. In two randomised, blinded, controlled clinical trials in people undergoing 
elective colorectal surgery found that patients receiving LR blood had a significantly higher 
frequency of surgical site infections, nosocomial infections or intra-abdominal abscesses 
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than those receiving either no transfusion or post-storage LR blood.186, 187 A newer double-
blinded, randomised controlled clinical trial performed in almost 500 patients that had 
cardiac valve surgery similarly found patients that received LR blood had a significantly 
reduced infection rate, compared to those that received NLR or BCP RBCs.188  Different to 
this finding however, a randomised clinical trial in a similar number of patients (n=597) 
undergoing elective coronary artery or heart valve surgery found no significant difference 
in inpatient infection rates following surgery amongst patients that received BCP or LR 
RBCs.189 Additionally, a single-center, randomised, double blinded trial evaluated post-
operative infection complications rates as a primary end point in 268 trauma patients 
requiring surgery that received either LR or NLR RBCs. Post-operative infectious 
complications evaluated included pneumonia, blood stream, surgical site and urinary tract 
infections, pseudomembranous colitis and any other infections identified with a positive 
microbial culture. The authors found a small but statistically non-significant effect on the 
infection complication between the two study groups.190 While it appears from these 
studies that leukoreduction does not consistently decrease the risk of post-operative 
infections, it appears to be protective in some groups, particularly in people having 
elective colorectal surgical procedures. 
 
2.4.3. Effect of leukoreduction on length of hospitalisation in people receiving transfusions 
The duration of hospital stay for patients is a common secondary outcome 
measure in several studies evaluating the effects of leukoreduction. Currently, it remains 
unclear if leukoreduction helps to reduce length of hospitalisation (LOH) in people 
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receiving transfusions. Van de watering et.al. evaluated cardiac surgical patients that 
received pre-storage LR (n=305), post-storage LR (n= 303), and BCP RBCs (n=306). There 
was no statistical difference between groups in length of hospitalisation.191 However, a 
multicenter, randomised, double-blinded clinical trial in 1051 surgical patients found 
those transfused LR rather than BCP RBCs during their major vascular or gastrointestinal 
surgery had a significantly shorter (2.4 days) length of hospital stay.192 Additionally, 
another multi-center study performed in 642 surgical patients with colorectal cancer 
requiring curative surgery randomised their patients to receive LR or NLR RBCs, and found 
the NLR group had significantly higher proportions with prolonged (>20 days) hospital 
stays. In both studies, there was no difference in overall survival between patients 
between the two study groups, hence eliminating the possibility that mortality rate was a 
cause for a shorter hospitalisation stay in patients receiving LR RBCs.193 A shorter 
hospitalisation stay presumably helps to reduce health care costs, however this needs to 
be weighed up against the cost of the entire leukoreduction process. There is currently 
insufficient evidence to prove that leukoreduction helps to reduce duration of 
hospitalisation in recipients, however it is also important to note that LOH was not 
evaluated as a primary outcome in these studies, and therefore these studies were not  
statistically designed to evaluate LOH in recipients. To determine if leukoreduction truly 
affects LOH, further studies will need to be conducted with LOH as a primary outcome 
measure.   
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2.4.4. Effect of leukoreduction on multi-organ dysfunction syndrome in people receiving 
transfusions 
Multiple organ dysfunction syndrome (MODS) is defined as a potentially life-
threatening, progressive, physiologic derangement in two or more organ systems not 
involved in the underlying disorder, and in people, has been reported to be the main cause 
of morbidity and mortality in critically ill patients.194, 195 As such, many studies have 
evaluated incidence of MODS as primary or secondary outcomes in patients receiving LR 
or NLR RBCs.  
Acute kidney injury (AKI) is a common component of MODS in critically ill patients, 
and is diagnosed by a rapid decrease in kidney excretory function as indicated by 
elevations of creatinine, decreased urine output, or both.196, 197 It is a recognised 
complication post-cardiac surgery that increases morbidity and mortality in patients.198-
200 A large before-and-after cohort study evaluated the association of universal 
leukoreduction with AKI in 1034 patients that had coronary artery bypass grafting surgery, 
and found statistically significant decreases in AKI incidence from 51.7% before universal 
leukoreduction, to 41.5% after. In addition, multivariable analysis on all transfused 
patients found transfusion of NLR blood to be an independent predictor of AKI.201  
Pulmonary dysfunction from non-cardiogenic pulmonary oedema is also a 
common component of MODS in critically ill patients, classified as acute lung injury (ALI) 
or acute respiratory distress syndrome (ARDS).202 A single-center, double blinded clinical 
trial in 268 trauma patients randomised to receive LR or NLR RBCs within 24 hours of 
surgery, found no significant difference in the incidence of early (<72 hours) or late (>72 
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hours) ALI/ARDS between treatment groups. In addition, ventilator-free days were not 
statistically different between the two groups, suggesting that LR RBC transfusions had no 
effect on the development of ALI/ARDS.203 Similarly, a large retrospective cohort study 
also performed in trauma patients analysed patients in 3 different groups; patients that 
received LR RBCs, NLR RBCs, and a mixture of both. One of their primary outcomes 
measured was incidence of ARDS, with MODS severity score as a secondary outcome. The 
results of their study showed no differences between all 3 groups in ARDS incidence or 
MODS severity score.204 While leukoreduction appears to have some benefit in reducing 
the incidence of AKI in critically ill transfusion recipients, there is conflicting evidence as 
to the benefit it provides in decreasing the incidence of ALI or ARDS or the risk or severity 
of MODS in patients with acute critical illness. There are currently no studies evaluating 
the effects of leukoreduction in patients with chronic illnesses.   
 
2.4.5. Effect of leukoreduction on mortality in people receiving transfusions 
As previously discussed, there is evidence that the use of leukoreduced blood 
products can reduce morbidity by reducing incidences of FNHTR, AKI, post-operative 
infections, and length of hospitalisation in different populations of transfusion recipients. 
While several studies have shown that leukoreduction has no benefit on mortality, there 
is overall disparate evidence on this. A before-and-after cohort study performed at a level 
one trauma center reported no difference in mortality between groups of patients that 
received LR or NLR RBCs, however was likely underpowered to detect a difference.205 
Similar findings were reported in a double-blinded clinical trial in 474 surgical patients 
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randomised to receive BCP or LR RBCs. The investigators found that their primary end 
point of mortality at 90 days was not statistically different between the two treatment 
groups.188 A 15-year follow up study of elective colorectal surgical patients were 
categorised into three groups; those that received LR, BCP, or no RBC transfusions. While 
they found significant differences in 15 year survival between the transfused and non-
transfused groups, where the transfused group lived longer, there was no difference 
identified when compared between patients that received LR or BCP RBCs.206 Several 
more studies have also reported no significant differences in mortality as primary end 
points in patients that received LR blood products, compared to those that received BCP 
or NLR blood products.186, 191-193 Conversely, there are other studies that demonstrated a 
lower mortality in groups of patients that received LR RBCs, compared to those that 
received NLR RBCs. In 2003, a national universal leukoreduction program performed in 
Canada reported significantly lower in-hospital mortality rates from 7.03% to 6.19% 
following implementation of leukoreduction.169 While other studies have reported some 
reduction in observed mortality rates in the groups of patients that received LR RBCs, 
these findings were not statistically significant.201, 207 The effect of leukoreduction on 
patient mortality in people remains unclear, and further prospective clinical trials should 




2.4.6. Universal leukoreduction implemented in human blood banks  
Given evidence of the potential benefits of leukoreduction in people, several 
countries started to implement universal leukoreduction in their blood banks. Following 
implementation of universal leukoreduction, the change in incidence of FNHTR in people 
has since been investigated in several large-scale, retrospective, randomised, controlled 
clinical trials.14, 27, 170, 171 In all studies, there was a significant reduction in FNHTR incidence 
after implementation of universal leukoreduction. A more recent large before-and-after 
study evaluated acute transfusion reactions prior to and after implementation of universal 
leukoreduction in a university teaching hospital and showed similar results, where a 
significant reduction in FNHTR rates by 35% was observed following universal 
leukoreduction.208 Another large retrospective clinical trial performed in Canada following 
implementation of universal pre-storage leukoreduction also evaluated post-transfusion 
FNHTR as a secondary outcome, and found that it decreased significantly following 
leukoreduction.169 These studies have shown a clinical benefit of universal pre-storage 
leukoreduction in human patients. As such, given the potential for multiple benefits and 
the relatively negligible additional cost of leukoreduction, many countries including 
Canada, Finland, France, Germany, United Kingdom have mandated universal 




2.4.7. Effect of leukoreduction in pre-clinical canine transfusion recipients  
The effect of leukoreduction on inflammation in canine transfusion recipients is 
largely limited to preclinical studies in healthy dogs. Unfortunately, even within 
populations of healthy dogs, the benefit of leukoreduction is unclear due to conflicting 
results in two separate studies. In the first study, dogs receiving autologous NLR packed 
RBCs had significant increases in segmented neutrophils, fibrinogen, and C-reactive 
protein levels post-transfusion, compared with dogs receiving autologous LR packed RBC,8 
eliciting the conclusion that LR packed RBC are less pro-inflammatory than NLR packed 
RBC. On the other hand, a separate experimental study performed in healthy dogs 
assessing a different set of inflammatory biomarkers found no significant differences in 
concentrations of IL-6, IL-8, and MCP-1 between dogs receiving LR or NLR autologous 
packed RBC transfusions,9 prompting the conclusion that leukoreduction does not prevent 
transfusion-triggered inflammation, and perhaps there is no clinical benefit to 
leukoreduction. The benefits of leukoreduction in healthy dogs remains unclear, and 
further studies would be required to evaluate this.  
 
2.4.8. Effect of leukoreduction in clinical canine transfusion recipients  
There is some evidence in clinical canine patients that transfusion of leukoreduced 
blood may trigger less inflammation than non-leukoreduced blood. One prospective 
randomised clinical study evaluated the effects of leukoreduction on inflammatory 
biomarkers in 23 hospitalised dogs receiving a blood transfusion.217 The authors found 
that dogs receiving NLR packed RBC had a significantly higher total leukocyte count 24 
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hours following transfusion, compared to dogs receiving LR packed RBC, suggesting that 
leukoreduction may promote less inflammation in critically ill canine transfusion 
recipients. However, other inflammatory biomarkers including fibrinogen and C-reactive 
protein levels were not different between groups. Several aspects of this study make its 
findings challenging to interpret. Firstly, its small sample size likely precluded the authors 
from finding a difference between groups. Secondly, nearly half the population had 
immune-mediated haematologic disorders, for which they would have been receiving 
immunosuppressive agents. The medications may have acted to suppress a transfusion-
triggered inflammatory response in these patients, which would have made it challenging 
to find a difference between groups, especially in light of the small sample size. While this 
pilot study did not provide strong evidence for the use of leukoreduction to reduced 
transfusion-triggered inflammation in critically ill dogs, the results from this study 
provided information to help design future clinical trials to help answer this question. 
 
2.4.9. Universal leukoreduction in veterinary blood banks  
Leukoreduction now occurs universally in human blood banking in many countries, 
however, it is still uncommonly performed in veterinary medicine.209, 210 A 2012 
transfusion practice survey of 73 private referral hospitals and veterinary teaching 
hospitals in Canada, the United States, Europe, and Australia found only two hospitals 
performed leukoreduction using leukocyte reduction filters.144 This survey was however 
over-represented by respondents in the US (n= 62/73, 85%), and does not include 
information from commercial blood banks. The number of practices/hospitals that 
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perform leukoreduction in Australia remains unknown, however onea of the two 
commercial canine blood banks does perform leukoreduction on their RBC units. One 
reason leukoreduction is not performed commonly is due to the additional cost of 
leukoreduction filters and processing time required. Compared to human transfusion 
medicine, clinical trials supporting the use of leukoreduced RBC are lacking in veterinary 
medicine. Without strong evidence of improved outcome with this technique, it remains 
difficult to justify the cost of implementation of leukoreduction in veterinary blood 
banking.   
 
2.5. Footnotes 
a. Plasvacc Pty Ltd, Kalbar, Queensland, Australia.  
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3. Chapter 3: Transfusion practice in Australia: An internet-based survey  
3.1. Abstract 
Objective: Describe small animal transfusion practices in Australia, including access to 
blood products, and frequency of pre-transfusion compatibility testing and medication 
administration. 
Methods: An online survey was disseminated to target Australian veterinarians treating 
dogs and cats. Information collected included demographics, sources of blood products, 
blood storage, recipient compatibility testing, and administration of medications pre-
transfusion. Associations between the use of compatibility tests and premedications were 
assessed using the χ2 test. Significance was set at P<0.05.  
Results: 199 Australian veterinarians were included, however there was some attrition of 
respondents over the course of the survey. The majority of respondents were in general 
practice (n=133/199). Access to fresh whole blood was commonly reported for dogs 
(n=179/199) and cats (n=131/198), whereas blood components were less commonly 
available (canine red blood cells (RBC), n=52/199, and plasma, n=157/199; feline RBC, 
n=9/198 and plasma, n=21/198). Most blood was sourced from the pets of owners 
affiliated with the veterinary clinic (n=179/196). The respondents who did not blood type 
or cross-match dogs were significantly more likely to use premedication than those who 
did these tests (both comparisons: P<0.001). Likewise, the respondents who did not blood 
type cats were significantly more likely to use premedication (P=0.003), however there 
was no association between cross-matching and using premedication in cats (P=0.183).  
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Conclusion: This is the first survey to describe transfusion practices across a variety of 
practice types throughout Australia. Future work is needed to determine how 
representative these results are of current transfusion practices across Australia, and if so, 
what can be done to optimise them. 
 
Keywords: blood components; blood type; cross-match; premedication 
Abbreviation 
24H  24-hour veterinary hospital 
AHO  After-hours only emergency veterinary hospital 
FFP  Fresh frozen plasma 
FWB  Fresh whole blood  
GP  General practice 
PRBC  Packed red blood cells 
SRH  Specialist referral hospital (includes academic and private) 
SWB  Stored whole blood  
 
3.2. Introduction 
Blood transfusion practices employed by small animal veterinarians are poorly reported 
in the literature. Of just two peer-reviewed publications available, both were surveys 
focused primarily on veterinary transfusion practices in North America, and only one of 
these gathered information from general practitioners nearly 3 decades ago.1,2 The more 
recent publication only surveyed specialty referral hospitals (SRH), primarily located 
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within the United States. This survey of 73 SRH (both private and academic) was 
conducted to determine if their transfusion practices were aligned with ‘best practice’.2 
‘Best practice’ is a set of clinical decisions based on the expert interpretation of current 
scientific evidence. In transfusion medicine, ‘best practice’ can currently be defined as 
transfusing blood components rather than whole blood,3-8 storing blood products in a 
dedicated storage unit,3-5,9,10  compatibility-testing recipients pre-transfusion,3,4,7,8,11-20 
and avoiding routine premedication.21-29 There was overall good alignment of the SRH 
with ‘best practice’ recommendations, where 99% routinely transfused dog and cat blood 
components, over 50% stored blood products in dedicated refrigerators or freezers, 96% 
performed compatibility testing in dogs and cats, and only 8% routinely premedicated 
recipients.2 While the results of that survey are promising, it cannot be assumed that they 
would represent the current transfusion practices in all types of Australian veterinary 
clinics.  
 
Different to the United States where there are multiple commercial sources of cat and dog 
blood components,30 in Australia, the commercial availability of canine blood products 
that can be shipped nationally is extremely limited, and there is no commercial availability 
of feline blood products. Limitations in blood product availability may compromise the 
ability of Australian veterinarians to adhere to the ‘best practice’ recommendation to 
transfuse blood components rather than whole blood.3-8 Indeed, half of the SRH in the 
aforementioned survey obtained their cat and dog blood components from commercial 
sources.2 Due to the paucity of commercial resources, Australian veterinarians must 
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identify other sources to provide their patients with blood transfusions. These may 
include establishing an in-house blood bank, or referring patients to veterinary hospitals 
with in-house blood banks, however the frequency with which this occurs has not been 
described in Australia.  
 
There is no consensus statement or set of clinical guidelines to outline all aspects of ‘best 
practice’ in small animal transfusion medicine. However, there are many peer-reviewed 
and non-peer-reviewed publications that have summarised relevant studies and may, 
when taken together, approximate what can conclusively be considered ‘best practice’.3-
28,31-35 Australian veterinary transfusion practices including sourcing, handling, and 
administering canine and feline blood products, are wholly unreported in the literature. 
Gaining a broader understanding about what occurs in actual practice across a variety of 
hospital settings will allow for comparison between current practice and ‘best practice’. 
Where incongruities are found, a more directed assessment can then help determine 
causation, with the ultimate goal to bring current Australian transfusion practice into 
alignment with ‘best practice’. 
 
Therefore, the overall aim of this study was to survey Australian companion animal 
veterinarians to gain a preliminary understanding of current small animal transfusion 
practices throughout the country. Our primary objective was to describe varieties and 
sources of dog and cat blood products, and frequency by which pre-transfusion practices 
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were performed, including cross-matching, blood typing, and premedication 
administration.  
 
3.3. Materials and methods 
The study survey was approved by the university’s human research ethics committee 
(2018/030).  
 
The survey questions were composed in an online cloud-based survey software 
(SurveyMonkey, San Mateo, California, United States). The survey inclusion criteria were 
all small animal and mixed (small and large) animal veterinarians in Australia. Respondents 
who did not consent to participate, as well as those who practiced outside of Australia, 
and those who did not treat cats or dogs were excluded. Additionally, when multiple 
responses were linked to identical internet protocol addresses, all but the initial survey 
response were excluded. Finally, a respondent was excluded if they answered they had no 
access to both dog and cat blood, and if a respondent reported access to only dog or cat 
blood, any answers provided on compatibility testing or premedication for the species 
they do not transfuse were excluded. These exclusions sharpened the focus of the survey 
to actual transfusion practices by Australian veterinarians, rather than theoretical 
transfusion practices by veterinarians who do not typically administer them. A web link to 
the survey was created, and disseminated via email, social media, and veterinary 
surgeons’ boards. Specifically, hospital email addresses were obtained via an internet 
search to identify after-hours, emergency, and specialist hospitals in all states and 
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territories. Once identified, an invitation including the survey’s web link was emailed to 
hospital email addresses. This same web link was also posted on several closed Australian 
veterinary social media discussion forums, with access to veterinarians only. Finally, the 
web link was emailed to the veterinary surgeons’ board of each state for dissemination to 
registered members. The survey was first disseminated on the 10th of May, 2018 and the 
survey was closed on the 1st of October, 2018.  
 
The survey consisted of 19 questions (Appendix 1). Questions were displayed on individual 
pages in sequential order. All questions required an answer before the respondent could 
move to the next question, and each response was saved as the respondent advanced to 
the next question. If a respondent exited the survey prior to its completion, all completed 
responses were saved through the last answered question. The first 4 questions were used 
to obtain the participant’s consent, and the next 5 were used to obtain respondent 
demographics. The remaining 10 questions were organised to obtain information on 
sourcing of blood products for dogs and cats, blood product storage logistics, and finally 
recipient screening and use of pre-medications prior to transfusion for dogs and cats.  The 
multiple-choice answer options included a variety of only 1 answer possible, more than 1 
answer possible, yes/no answers, and an ‘Other’ option where free text could be entered. 
All answered questions by included respondents were incorporated in descriptive 




Due to feedback provided in questions 17 and 19 by some respondents who were 
dissatisfied with the multiple-choice selections in questions 16 and 18, an additional 
answer option of “other or none” with a free text box was included for these two 
questions on the 20th of June, after the first 124 responses had been collected. Following 
data collection and removal of excluded respondents, the responses of the first 103 
included respondents were evaluated for inconsistencies between the selected response 
in questions 16 and 18 and their free text entries in questions 17 and 19. The initial 
selections in questions 16 and 18 were changed if it was clear from their free text entries 
they were dissatisfied to not have a choice of “other or none” in the previous questions.  
 
Statistical methods 
Statistical analyses were performed with commercially available software (IBMSPSS 
Statistics Version 24, Microsoft Excel for Mac, Version 16.17, http://www-
01.ibm.com/software/uk/analytics/spss/, RRID:SCR_002865). Descriptive statistics with 
proportions are reported for respondent demographics, blood product availability, and 
pre-transfusion testing and medication administration. Associations between the use of 
pre-transfusion compatibility testing and premedication administration were assessed 
using the χ2 test, and results are reported as odds ratios with 95% confidence intervals. A 





Two hundred and thirty-five survey responses were obtained between May and October 
2018. Thirty-six respondents were excluded, leaving 199 respondents included in the 
study. Reasons for exclusion included lack of consent for publication (n=1), practicing 
outside of Australia (n=1), not treating dogs and cats (n=2), duplicate internet protocol 
addresses (n=9), survey dropout after demographic section completed (n=10), and 
reporting no access to both dog and cat blood products (n=13). For the included 199 
respondents, there were 9 individual modifications made to respondents’ answers 
provided for questions 16 and 18 prior to the change made on the 20th of June, as 
described above. All 9 modifications were a change from “premedication” to “none” to 
reflect the free text comments in questions 17 and 18. Furthermore, 65 respondents had 
their answers for questions 18 and 19 excluded from analysis, as they reported no access 
to cat blood products in question 11 (n=61), or commented they do not transfuse cats in 
question 19 (n=4). 
 
Respondent demographics (n=199) 
The largest proportions of respondents practiced in Western Australia (n=76, 38.2%) and 
New South Wales (n=49, 24.6%), with lesser numbers in Victoria (n=32, 16.1%), 
Queensland (n=20, 10%), South Australia (n=10, 5%), Northern Territory (n=7, 3.5%), 
Tasmania (n=3, 1.5%), and the Australian Capital Territory (n=2, 1%). Most were 
exclusively small animal veterinarians (n=148, 74.4%), followed by mixed animal 
veterinarians (n=51, 25.6%). Half of respondents practiced in suburban veterinary clinics 
 100 
(n=98, 49.2%), with lesser numbers in rural clinics (n=66, 33.2%), and urban (inner city) 
clinics (n=35, 17.6%).  
 
The majority of respondents selected general practice (GP) as practice type (n=133, 
66.8%), with lesser numbers selecting specialty referral hospital (SRH; n=30, 15.1%, with 
22 in private and 8 in academic hospitals), 24-hour veterinary hospital (24H; n=20, 10%), 
and after-hours only hospitals (AHO; n=16, 8%). The majority of respondents worked in 
small veterinary clinics with 1-5 veterinarians on staff (n=94, 47.2%), with lesser numbers 
in practices with 6-15 veterinarians (n=58, 29.1%), and over 15 veterinarians (n=47, 
23.6%).  
 
Blood product availability – dogs (respondents, n=199) 
The range of products available to respondents included fresh whole blood (FWB) (n=179, 
89.9%), fresh frozen plasma (FFP) (n=157, 78.9%), stored whole blood (SWB) (n=71, 
35.7%), and packed red blood cells (PRBC) (n=52, 26.1%). Twenty-seven respondents 
(13.6%) reported having access to all 4 of these products. Other products noted to be 
available included cryoprecipitate (n=2), frozen plasma (n=1), and platelet-rich plasma 
(n=1). One respondent who had access to FWB and SWB commented that other blood 





Blood product availability – cats (respondents, n=198) 
The majority of respondents had access to FWB (n=131, 66.2%); however, a large 
proportion of respondents reported they did not have access to any cat blood products 
(n=61, 30.8%). Some had access to FFP (n=21, 10.6%), SWB (n=12, 6.1%), and PRBC (n=9, 
4.5%). Only 3 respondents (1.5%) had access to all 4 of these products. One respondent 
noted they make fresh plasma on site. Two respondents commented that while they do 
not have access to cat blood, they do have access to dog FWB for xenotransfusion when 
required. One other respondent had access to cat FWB, but also commented in question 
18 that they have used dog blood for cat transfusions. 
 
Sourcing blood products (respondents, n=196) 
The majority of respondents reported they sourced blood products from dogs and cats 
owned by staff members, friends, and acquaintances (179, 91.3%). Additionally, 
respondents also sourced commercially available blood products (n=122, 62.2%), or used 
community blood donors (n=92, 46.9%). Small numbers of respondents sourced blood 
products from terminal donors (n=18, 9.2%). Other sources of blood products included 
patient referral to a specialist hospital for transfusion (n=2), healthy shelter animals (n=2), 
healthy dogs destined for euthanasia (n=1), non-terminal greyhounds housed with 
trainers (n=1), and acquired from a local emergency hospital (n=1). The majority of 
respondents collected blood with the intention to administer it immediately (n=133, 
67.9%), while a smaller number collected blood with the plan to store it for later use 
(n=55, 28.1%).   
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Storing blood products (respondents, n=194) 
Respondents were then asked to provide their typical PRBC or SWB length of storage time, 
and 77 (39.7%) respondents reported they never stored cell-containing blood products. 
Of the 117 (60.3%) respondents who noted a storage time, the majority stored PRBC or 
SWB for 22-42 days (n=56) or 7-21 days (n=42), with fewer storing for less than 7 days 
(n=17) and more than 42 days (2). Only 35 respondents reported storing SWB/PRBC or 
plasma in a refrigerator or freezer dedicated to blood product storage. Two of the 35 
respondents reported access to FFP as their only stored blood product. The respondents 
who reported having dedicated storage units for blood products were primarily from SRH 
(n=21) and 24H (n=9), with fewer from AHO (n=4) and GP (n=1). Of the remaining 159 
respondents reporting no dedicated storage unit, 55 reported access to SWB, PRBC, or 
both, whereas 18 reported access to FFP as their only stored blood product, and 31 
reported access to no stored blood products. 
 
Pre-transfusion compatibility testing and premedication in dogs (respondents, n=186) 
Nineteen respondents (10.2%) reported performing blood typing only, 31 (16.7%) 
reported performing cross-matching only, and 42 (22.6%) reported both blood typing and 
cross-matching pre-transfusion. Ten respondents clarified that a prior history of 
transfusion influenced their decision to perform pre-transfusion compatibility testing.  
 
Just over half of the respondents (n=100, 53.8%) report administering medication prior to 
starting transfusions in dogs. Chlorpheniramine was the most commonly administered 
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premedication choice (n=82, 44.1%), while steroids were less commonly given (n=37, 
19.9%). Other medications respondents commented on administering included sedatives 
(n=4, 2.2%), and adrenaline (n=1). Fifty-two respondents (28%) specifically commented 
they do not routinely administer any premedications.   
 
The relationship between pre-transfusion compatibility testing and administration of the 
premedications associated with hypersensitivity reactions was then explored further. The 
respondents who did not perform blood typing or cross-matching in dogs were 
significantly more likely to use premedication than those who blood typed or cross-
matched (both comparisons: P<0.001, Table 1). Specifically, the odds ratio of 
premedicating in the group that blood type relative to those that do not blood type was 
0.282 (95% CI 0.147-0.541). Similarly, the odds of premedicating in the group that 
crossmatch relative do those that do not crossmatch was 0.34 (95% CI 0.184-0.626). 
 
Pre-transfusion compatibility testing (respondents, n=123) and premedication 
(respondents, n=97) in cats  
Thirty-four of 123 respondents (27.6%) reported only blood typing, 32 (26%) reported 
only cross-matching, and 42 (34.1%) reported both blood typing and cross-matching prior 
to transfusing cats. One respondent with reported access to feline FWB listed that they 
‘have used canine blood’, and did not report blood typing, cross-matching, or 
premedicating recipients. There were two other respondents that were within the group 
of 61 respondents excluded from this section due to reported lack of access to feline blood 
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products. However, their use of canine blood to transfuse cats was deemed noteworthy 
to mention their responses to questions 18 and 19. One of these two respondents 
reported cross-matching prior to transfusion, and both reported premedicating recipients 
with chlorpheniramine. 
 
Of the 97 respondents answering the final question, 46 (47.4%) reported administering 
chlorpheniramine, 21 (21.6%) reported giving steroids, and 2 (2.1%) reported 
administering sedatives. Thirty-seven respondents (38.1%) specifically commented they 
do not routinely administer any premedications to cats.   
 
Similar to the relationship found with pre-transfusion practices in dogs, the respondents 
who did not blood type cats were significantly more likely to use premedication (P=0.003). 
Specifically, the odds ratio of premedicating in the group that blood type relative to those 
that do not blood type was 0.328 (95% CI 0.154-0.695). Different to pre-transfusion 
practices in dogs however, there was no association between performing cross-matching 
and premedicating cats (P=0.183, Table 1). The calculated odds ratio of premedicating in 







Table 1. Comparison of premedication use between respondents that do and do not  
use pre-transfusion compatibility testing, displayed as a series of 2x2 tables.  
 Premedication (dogs)  
 Yes No Total respondents 
Blood typing (dogs), P<0.001 
Yes 19 42 61 
No 77 48 125 
Total Respondents 96 90 186  
Cross-matching (dogs), P<0.001 
Yes 26 47 73 
No 70 43 113 
Total Respondents 96 90 186  
 Premedication (cats)  
 Yes No Total Respondents 
Blood typing (cats), P=0.003 
Yes 25 50 75 
No 29 19 48 
Total Respondents 54 69 123  
Cross-matching (cats), P=0.183 
Yes 28 44 72 
No 26 25 51 




This survey has provided preliminary information on blood transfusion practices of 
veterinarians across a variety of veterinary hospitals in Australia. Importantly, while our 
results are not representative of the entire Australian veterinary community, we were able 
to capture details of transfusion practices of veterinarians in GP hospitals, with 66.8% of 
our respondents practicing in this setting. This is in contrast to a recent multinational study 
that surveyed only veterinarians from private and university SRH.2 We found that the ‘best 
practice’ recommendation of compatibility-testing cats, is largely being followed, with 
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87.8% of respondents using blood type, cross-match, or both. However other ‘best 
practice’ recommendations are not being followed, including transfusing blood 
components rather than whole blood and avoiding the routine use of premedications. The 
data reported here can be used to shape future surveys directed toward identifying factors 
impeding alignment of current Australian veterinary transfusion practices with ‘best 
practice’.   
 
Blood component therapy rather than administration of whole blood is considered ‘best 
practice’ by experts in transfusion medicine.3-8,31,33 We found, however, that most dog and 
cat blood components are not accessible to Australian veterinarians responding to our 
survey, with just 25% of reporting access to dog PRBC, and 4.5% and 10% reporting access 
to cat PRBC and FFP, respectively. There does appear to be good familiarity with the only 
reliably available commercial blood product in Australia, canine FFP, with nearly 80% of 
respondents reporting access. While blood component therapy is part of ‘best practice’, 
maintaining an inventory of blood components is challenging, particularly in a country 
with extremely limited commercially sold blood components. Commercially produced and 
sold blood products have been shown to be an important source of dog and cat blood 
components elsewhere, with 50% of SRH in one survey responding that at least a portion 
of their inventory comes from commercially purchased products.2 Without the option to 
purchase blood components, Australian veterinarians must establish in-house blood 
banks capable of producing blood components to maintain alignment with ‘best practice’. 
This is an expensive and time-intensive endeavour that may not be justified if frequency 
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of transfusion administration is low. If there were more commercially available blood 
products that could be shipped nationally, including to remote regions of Australia, there 
may be improved alignment of current transfusion practice with ‘best practice’. 
 
Storing blood products in a dedicated storage unit to ensure minimal exposure to 
temperature variability is considered ‘best practice’.3-5,9,32 Very few Australian 
veterinarians in this survey noted they had a storage unit that was dedicated to storing 
blood products alone. While this question did not require veterinarians to distinguish 
between storing RBC-containing blood products in a refrigerator and FFP in a freezer, no 
more than 20% of our respondents with access to SWB or PRBC keep these products in a 
refrigerator dedicated to this purpose. This low overall response for having a dedicated 
storage unit is concerning. Significant temperature variability occurs within refrigerators 
that are frequently being opened, which occurs with those containing medications and 
foods. At worst, fatal haemolysis has been reported with the administration of stored 
canine RBC that had been exposed to significant variations in temperature.10 While there 
is a clear indication to store RBC-containing products in a dedicated storage unit, this 
transfusion practice has not been widely adopted by the respondents in our survey. This 
may be due to infrequent administration of transfusions by many of our respondents, 
precluding the financial investment in a dedicated refrigerator. Unfortunately, we did not 
obtain information regarding frequency of transfusion administration by each respondent, 
and are unable to speculate further. 
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Another aspect of transfusion medicine that is clearly considered ‘best practice’ is 
administering type-specific, cross-match-compatible blood to avoid acute haemolytic 
transfusion reactions.3,4,7,8,11-20,31,34,35 While in an emergency, canine type DEA 1 negative 
blood is considered acceptable to transfuse to a naïve recipient without first blood typing 
or cross-matching, compatibility-testing must always be performed prior to transfusion in 
cats.19,20,31,34-37 Our results show that pre-transfusion compatibility testing amongst the 
veterinarians surveyed is inconsistent with ‘best practice’, with only half of respondents 
performing these tests in dogs, and 87.8% of respondents performing these tests in cats. 
There are several possible reasons for this inconsistency. Firstly, as the majority of 
veterinarians in this survey source their blood from pet owners affiliated with the clinic, 
there may be very limited numbers of donors from which to collect blood. Recipient 
testing may be considered impractical in these situations, where even incompatible blood 
may be considered better than no blood at all. Also, veterinarians may test their canine 
donors and keep only DEA 1 negative dogs in their donor pool, which can limit the risk for 
immunologic transfusion reactions in naïve recipients. Secondly, respondents may be 
unable to easily access commercial blood typing or cross-matching kits, and may be 
unaware of how to perform these tests in-house without a kit, using more readily 
accessible materials. Thirdly, clients may be declining the use of these tests due to their 
additional cost, preventing veterinarians from providing this standard of care. Going 
forward, strategies to work toward improving alignment with ‘best practice’ include 
informing veterinarians of avenues to obtain affordable blood typing and cross-matching 
kits, and providing resources on logistics of performing cross-matches without a 
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commercial kit.31,34,35 It will also be important for veterinarians to educate clients on the 
potentially fatal risk of transfusing incompatible blood to their pet, which may improve 
client acceptance of the costs associated with pre-transfusion compatibility testing.  
 
More than 50% of our respondents report pre-medicating dogs and cats prior to 
transfusion, with chlorpheniramine being the most commonly administered 
premedication. We also found a relationship between performing compatibility testing 
and using premedication, where respondents who did not blood type dogs and cats were 
significantly more likely to administer a premedication than those who did blood type. A 
similar relationship was found with cross-matching, where respondents who did not cross-
match dogs were significantly more likely to administer a premedication than those who 
did cross-match. One potential cause for this finding may be that respondents administer 
premedication in lieu of compatibility testing, believing the medication may reduce the 
risk of a transfusion reaction. While type 1 hypersensitivity reactions may develop during 
or following transfusions, the current evidence does not support the use of premedication 
in people22-27,29 and dogs.28 Importantly, premedication does not prevent fatal acute 
haemolytic transfusion reactions, and should never be used in place of appropriate pre-
transfusion compatibility testing.  
 
Overall, the results of this survey on transfusion practices revealed inconsistencies 
between ‘best practice’ and current practice by Australian veterinarians. We postulate the 
absence of peer-reviewed, expert-led, evidence-based, open-access consensus 
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statements on veterinary transfusion practices to provide guidance that is current, 
underpinned by scientific evidence, and applicable to everyday clinical practice is playing 
a role in this misalignment.38,39 While there are calls for a broad set of peer-reviewed 
evidence-based guidelines outlining ‘best practice’ in veterinary transfusion medicine,12,32 
there is currently only one recent peer-reviewed, expert-led, open-access consensus 
statement on infectious disease testing of potential blood donors.14 Therefore, 
veterinarians aiming to practice high quality veterinary transfusion medicine using an 
evidence-based approach need to undertake the time consuming and financially costly 
activity of accessing and critically interpreting peer-reviewed studies and review articles 
often available only through subscription, and non-peer-reviewed expert opinion pieces 
in conference proceedings and textbooks, to cobble together their definition of ‘best 
practice’. The time and financial commitment required for a systematic review is a sizeable 
barrier, especially for those veterinarians who do not frequently transfuse patients. 
Therefore, without this task being performed by experts to generate clinical guidelines, 
the status quo will likely be maintained, and suboptimal transfusion practices will continue 
to compromise patient outcomes. 
 
Our study had some limitations. Firstly, while we deleted multiple responses from 
identical internet protocol addresses, we were unable to identify and to exclude responses 
from colleagues within the same hospital if they answered the survey from a separate 
location. Therefore, respondents may not be representing independent practices, which 
increases the risk of a type 1 error. Secondly, our survey was distributed to capture a 
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convenience sample of interested self-enrolled veterinarian participants. The results are 
hypothesis-generating, but are not necessarily representative of the entire Australian 
veterinary population. Along these lines, we had a higher response rate from WA than the 
other states and territories. Thus, our results may be biased towards transfusion practices 
in WA. Another limitation is that we didn’t have a lead-in period of our survey, where it 
was distributed to a small population to assess its efficacy in obtaining valid data. It wasn’t 
until the data collection was complete that we recognised some of our questions could 
have been more clearly worded to ensure capture of the desired information. Lastly, we 
omitted questions that could have better helped us characterise our patient 
demographics, including requesting full time equivalent veterinarians rather than total 
veterinarians, numbers of patients treated annually in each hospital, and requesting an 
estimated frequency of transfusion delivery within each practice. 
 
In conclusion, this is the first survey to describe the transfusion practices across a range 
of different veterinary hospitals in Australia, including a large number of GP hospitals. We 
found there are inconsistencies between current practice and ‘best practice’, especially in 
relation to use of WB instead of blood components, and insufficient pre-transfusion 
compatibility testing in cats. Future work is needed to determine how representative 
these results are of current transfusion practices across Australia, and if so, what can be 
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Appendix 1 =Transfusion practices: Sourcing dog and cat blood products for clinical use, 
and pre-transfusion interventions: a survey of Australian veterinarians 
 
Survey question Available responses 
Q1. I confirm that I have read and understand the 
information sheet for the above study and have had 
the opportunity to ask questions 
Yes 
No 
Q2. I understand that my participation is voluntary 
and that I am free to withdraw at any time 
Yes 
No 
Q3. I agree to take part in the above study Yes 
No 
Q4. I consent for the use of data collected in this study 
to be presented at future scientific meetings, to be 




Q5. Type of veterinary practitioner Small animals exclusively 
Mixed (Small and large) 
Equine exclusively 
Production animal exclusively 
Exotics exclusively 










I do not practice in Australia 
Q7. Region where veterinary clinic is located Rural 
Suburban 
Urban (Inner city) 
Q8. Type of practice General practice 
After-hours emergency hospital 
24-hour hospital 
Specialist referral hospital (Private) 
Specialist Referral hospital (Academic) 
Q9. Size of practice 1-5 veterinarians 
6-15 veterinarians 
>15 veterinarians 
Q10. Which of the following blood products are you 
able to access for administration to DOGS in your 
practice? 
Whole blood (fresh) 
Whole blood (stored) 
Packed red blood cells 
Fresh frozen plasma 
None of the above 
Other (Please specify) 
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Q11. Which of the following blood products are you 
able to access for administration to CATS in your 
practice? 
Whole blood (fresh) 
Whole blood (stored) 
Packed red blood cells 
Fresh frozen plasma 
None of the above 
Other (Please specify) 
Q12. How do you currently source blood products for 
your veterinary practice? 
Community (client/volunteer) blood donation 
program 
Staff members and/or friend/acquaintance dog/cat 
Terminal (i.e. ex-racing greyhounds donated for 
euthanasia) 
Commercially available blood products 
You are unable to source blood products 
Other (Please specify) 
Q13. If you collect blood products at your practice, are 
they collected on an as-needed basis or do you have 
the ability to store blood products? 
Collected when needed and administered 
immediately 
Stored for later use 
We do not collect blood products at my practice 
Q14. If you store whole blood or packed red blood 
cells, how long do you store them before you discard 
them? 
Not stored 
Stored for < 7days 
Stored for 7-21 days 
Stored for 22-42 days 
Stored for >42 days 
Q15. Do you store your blood/plasma in a refrigerator 




Q16. Do you perform any of the following, prior to 




Other or none (Please specify) 




Other or none (Please specify) 
Q18. Do you perform any of the following, prior to 




Other or none (Please specify) 




Other or none (Please specify) 
Survey question Available responses 
Q1. I confirm that I have read and understand the 
information sheet for the above study and have had 
the opportunity to ask questions 
Yes 
No 
Q2. I understand that my participation is voluntary 




Q3. I agree to take part in the above study Yes 
No 
Q4. I consent for the use of data collected in this study 
to be presented at future scientific meetings, to be 




Q5. Type of veterinary practitioner Small animals exclusively 
Mixed (Small and large) 
Equine exclusively 
Production animal exclusively 
Exotics exclusively 










I do not practice in Australia 
Q7. Region where veterinary clinic is located Rural 
Suburban 
Urban (Inner city) 
Q8. Type of practice General practice 
After-hours emergency hospital 
24-hour hospital 
Specialist referral hospital (Private) 
Specialist Referral hospital (Academic) 
Q9. Size of practice 1-5 veterinarians 
6-15 veterinarians 
>15 veterinarians 
Q10. Which of the following blood products are you 
able to access for administration to DOGS in your 
practice? 
Whole blood (fresh) 
Whole blood (stored) 
Packed red blood cells 
Fresh frozen plasma 
None of the above 
Other (Please specify) 
Q11. Which of the following blood products are you 
able to access for administration to CATS in your 
practice? 
Whole blood (fresh) 
Whole blood (stored) 
Packed red blood cells 
Fresh frozen plasma 
None of the above 
Other (Please specify) 
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Q12. How do you currently source blood products for 
your veterinary practice? 
Community (client/volunteer) blood donation 
program 
Staff members and/or friend/acquaintance dog/cat 
Terminal (i.e. ex-racing greyhounds donated for 
euthanasia) 
Commercially available blood products 
You are unable to source blood products 
Other (Please specify) 
Q13. If you collect blood products at your practice, are 
they collected on an as-needed basis or do you have 
the ability to store blood products? 
Collected when needed and administered 
immediately 
Stored for later use 
We do not collect blood products at my practice 
Q14. If you store whole blood or packed red blood 
cells, how long do you store them before you discard 
them? 
Not stored 
Stored for < 7days 
Stored for 7-21 days 
Stored for 22-42 days 
Stored for >42 days 
Q15. Do you store your blood/plasma in a refrigerator 




Q16. Do you perform any of the following, prior to 




Other or none (Please specify) 




Other or none (Please specify) 
Q18. Do you perform any of the following, prior to 




Other or none (Please specify) 

















4. Chapter 4: A comparison of inflammatory biomarker concentrations over time in critically 
ill dogs receiving leukoreduced or non-leukoreduced red blood cell transfusions: A 
randomised, blinded, controlled clinical trial 
4.1. Abstract 
Objective:  Compare inflammatory biomarkers concentrations including leukocyte count, 
interleukin (IL)-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), and C-reactive 
protein (CRP) over time in dogs administered leukoreduced (LR) or non-leukoreduced 
(NLR) red blood cell (RBC) transfusions.   
Setting:  Two university veterinary teaching hospitals 
Design:  Randomised, blinded, controlled clinical trial, with enrollment from July 2017 
through December 2018.  
Animals:  61 dogs prescribed a RBC transfusion that were not receiving 
immunosuppressive drugs, bolused blood, or anticipated to die or be discharged within 
24 hours of transfusion. 
Interventions:  Independent technicians randomised, collected, and processed blood bags 
into identically-appearing LR or NLR bags. Dogs were allocated to a study group when they 
were transfused with the oldest compatible RBC bag. Rectal temperature and blood 
samples were collected from recipients before transfusion, and at 8 and 24 hours after 
start of transfusion for leukocyte count, IL-6, IL-8, MCP-1 and CRP. Data were analyzed on 
an intention-to-treat basis using linear mixed effects models. Significance was set at 
P<0.05. 
 120 
Measurements and Main Results:  61 dogs (LR=34, NLR=27) were enrolled. Main reasons 
for transfusion included bleeding intra-abdominal mass and trauma. There were no 
significant differences between groups in body temperature (P=0.076), or concentrations 
of leukocytes (P=0.93), IL-6 (P=0.99), IL-8 (P=0.75), MCP-1 (P=0.69), or CRP (P=0.18) over 
time. Eleven dogs (32%) in the LR group and 4 dogs (15%) in the NLR group were 
euthanized in hospital (P=0.14). There were no natural deaths. 
Conclusions:  No differences in inflammatory biomarker concentrations were detected 
over time between dogs transfused LR or NLR RBC in this study, however individual 
variability likely hampered the ability to detect a difference with this sample size. The 
novel randomisation, blinding, and enrollment protocol was successfully implemented 
across two participating institutions, and will be easily scaled up for a future multicenter 
clinical trial.   
 
Keywords: Leukocytes, C-reactive protein, interleukin-6, interleukin-8, monocyte 
chemoattractant protein-1, febrile non-haemolytic transfusion reaction 
 
Abbreviations: 
CRP  C-reactive protein 
FNHTR  Febrile non-haemolytic transfusion reaction 
IL  Interleukin 
LR  Leukoreduced 
MCP-1  Monocyte chemoattractant protein-1 
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NLR  Non-leukoreduced  
RBC  Red blood cell 
 
4.2. Introduction 
Red blood cell (RBC) transfusions are life-saving in critically ill anemic and bleeding dogs, 
however they are not without risk. Allogenic RBC transfusions in critically ill people, and 
autologous RBC transfusions in healthy dogs induce an acute inflammatory response, 
evidenced by post-transfusion increases in leukocyte count and inflammatory cytokine 
concentrations.1-5 Transfusion-related inflammation may clinically manifest as a febrile 
non-hemolytic transfusion reaction (FNHTR), commonly defined in people as a rise in body 
temperature of at least 1°C during or shortly after a blood transfusion.6 Fever contributes 
to patient morbidity by causing chills and rigors that increase metabolic demand and 
oxygen consumption.7 An increase in body temperature temporal to RBC transfusions has 
also been reported in dogs, though consensus on the definition of FNHTR is lacking.8, 9  
Post-transfusion inflammation may result from administration of inflammatory mediators 
that accumulate in RBC products during storage.10 Specifically, interleukin (IL)-1β, IL-6, IL-
8, and tumor necrosis factor-α accumulate in human blood products over time.4, 11, 12 
Similarly, IL-8 concentration increases in canine RBC products over time, with an 
estimated peak between days 20 and 30.13-15 The source of accumulating cytokines are 
leukocytes and platelets within blood products, which can be removed prior to storage 
using a leukoreduction filter. In human medicine, leukoreduction has led to a significant 
decrease in prevalence of FNHTR, and can be considered a standard of care.16, 17  
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Leukoreduction prevents accumulation of IL-8 in canine stored RBC, and therefore may 
attenuate the acute inflammatory response after transfusion of older stored blood.13-15 A 
pre-clinical trial in healthy research dogs found leukoreduction significantly decreased the 
acute inflammatory response seen after transfusion of 21-day-old stored RBC compared 
with similarly aged non-leukoreduced (NLR) RBC.5 Conversely, a retrospective comparison 
of hospitalised dogs receiving variably-aged leukoreduced (LR) or NLR RBC found no 
difference in FNHTR between the two groups.8 Also, a recent prospective randomised pilot 
study in critically ill dogs transfused RBC stored fewer than 12 days found no difference 
over time in leukocyte, fibrinogen, and C-reactive protein (CRP) concentrations between 
the LR RBC-transfused and the NLR RBC-transfused dogs.18 Failure to find a difference 
between the two groups may have been due to the use of relatively fresh RBC with low 
levels of accumulated cytokines, or the inclusion of dogs receiving immunosuppressive 
therapy, which may have suppressed any post-transfusion inflammatory response. 
Overall, it remains unclear if leukoreduction mitigates post-transfusion inflammation in 
critically ill dogs. 
The aim of this randomised, blinded, controlled clinical trial was to assess the effect of 
leukoreduction on the post-transfusion acute inflammatory response in critically ill dogs. 
We hypothesised that dogs receiving LR RBC would have lower concentrations of 
leukocytes, IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), and CRP post-
transfusion over time compared with dogs receiving NLR RBC. Our secondary aim was to 
generate feasibility and outcome data to be used in planning a larger multicenter trial 
assessing clinical endpoints.  
 123 
4.3. Materials and methods 
This study was led by investigators at Murdoch University (MU) with University of 
Queensland (UQ) participating as a secondary study site. The study protocol was approved 
by MU (R2883/16) and UQ (SVS/568/17) Institutional Animal Ethics Committees.  
 
Randomisation and blinding 
An online random group allocation softwarea, accessible by both sites, was used to 
randomise all blood donations collected during the study period as LR or NLR. A blood 
bank technician at each site who was not involved with blood product administration or 
care of any enrolled patients was responsible for the blood collection and processing. Each 
RBC bag was assigned a unique code identifier, which was recorded in a password-
protected database. The technician labeled bags either ‘A’ or ‘B’, according to group 
allocation. As both LR and NLR bags had an otherwise identical appearance, clinical staff 
and investigators were blinded to the group allocations. Labeled RBC bags were stored 
together at 2-6 °C in a dedicated blood refrigerator, in order of expiratory date, freely 
available for clinical use for a maximum of 42 days. All patients requiring a blood 
transfusion received the next available compatible RBC bag, regardless of study eligibility. 
There was no additional randomisation occurring at study participant level. Unblinding 





Blood collection and processing 
Whole blood collection was performed routinely from community donors at MU and from 
a teaching colony of dogs at UQ.19  Additionally, at MU only, blood was collected from ex-
racing greyhounds as previously described.14 This blood collection protocol was approved 
by MU Institutional Animal Ethics Committee (NC3032/18).  
At both study sites, blood bags randomised into the LR groupb were held at room 
temperature (22-24°C) for up to 2 hours. Each bag was then gently mixed by hand, and 
the seal was broken to allow the fresh whole blood to flow by gravity through an integrally 
attached leukoreduction filterc into a satellite bag. Both LR and NLRd blood bags were then 
processed identically. Bags were centrifuged at 4000 x g for 10 minutes at 4 °C. After 
centrifugation, plasma was extracted into a satellite bag and removed. Finally, 100 mL of 
the RBC preservative, saline, adenine, glucose, and mannitol from another integrally 
attached bag, was added to the bag of RBC and gently mixed by hand. Bags were labeled 
with their group allocation (A or B), and placed in the dedicated blood refrigeratore,f for 
later use.  
 
Case selection and enrollment  
All dogs that were prescribed a RBC transfusion were eligible for inclusion in the study. 
Exclusion criteria included previous enrollment in this study, administration of 
immunosuppressive drugs within the previous 24 hours or anticipated in the next 24 
hours, delivery of a RBC bolus defined as a rate faster than or equal to 20 mL/kg/hr at any 
time during the transfusion, or anticipation of death, euthanasia, or discharge prior to 24 
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hours post-transfusion. Immunosuppressive drugs were defined as corticosteroids 
administered at immunosuppressive doses (e.g. prednisolone at ≥ 2 mg/kg/day or 
equivalent), or any dose of cyclosporine, azathioprine, mycophenolate, or leflunomide. 
Informed owner consent for study enrollment was obtained in-person or during a 
telephone conversation by a hospital clinician. A dog was allocated to the LR or NLR group 
by selection of the oldest type-compatible RBC bag in the blood bank. Cross-matching was 
performed at the clinician’s discretion. The clinician prescribing the RBC transfusion 
recorded patient allocation group, ‘A or B’, on the standardised case report form. Once a 
patient had been allocated to a group, all RBC administered within the 24-hour study 
period were from that same group. Dose and rate of delivery of RBC transfusion was at 
the discretion of the treating clinician.  
 
Sampling of blood 
Prior to starting the RBC transfusion, a 5 mL sample was aseptically collected from all RBC 
bags administered within the 24 hour study period. These samples were centrifuged, and 
supernatant stored at -80°C for later analysis of canine-specific IL-8.  
Blood samples were collected from the transfusion recipient at baseline (0 hours (h), 
defined as within 1 hour prior to the start of transfusion), and at 8 hours (8 h), and 24 
hours (24 h), from the start of transfusion. Blood collected into EDTA at each time point 
was used to perform an automated complete blood count within 24 hours of collection, 
using one of 3 hematology analysers.g,h,i Blood samples in lithium heparin tubes and 
serum separator tubes taken at each time point were immediately centrifuged at 7000 x 
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g for 10 minutes at 4°C, and separated into aliquots that were stored at -80°C until analysis 
of plasma IL-6, IL-8, MCP-1, and serum CRP.  
 
Monitoring and Data Collection 
Rectal temperature, heart rate, respiratory rate, indirect arterial blood pressure, and rate 
of transfusion administration were recorded on a standardised case report form 
(Appendix 1 in supplementary material) at the start of transfusion, then at 15, 30, and 60 
minutes later, with subsequent recordings at 60-minute intervals until the transfusion was 
complete. These parameters were also recorded at sampling time points 0 h, 8 h, and 24 
h. Monitoring and data collection were performed by clinical staff and final year veterinary 
students. Any observed signs consistent with a transfusion reaction (including urticaria, 
facial edema, acute hypotension, pigmenturia, tachypnea, ptyalism, regurgitation, or 
vomiting) were reviewed by the clinician on duty, who then decided if cessation of 
transfusion or treatment was indicated. All adverse events and interventions were 
recorded on the patient’s case report form. The ages of the transfused RBC bags in days 
for each dog were calculated and recorded on a patient demographic spreadsheet after 
study completion.  
 
Biomarker Analysis 
At the completion of patient enrollment, all frozen serum and plasma samples were 
shipped overnight on dry ice from UQ to MU for sample analysis. All analyses were 
performed using previously unthawed aliquots. Plasma canine-specific IL-6, IL-8, and 
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MCP-1 were measured in duplicate according to the manufacturers’ guidelinesj using a 
multiplexed magnetic bead biomarker analyser.k,l Canine-specific IL-8 concentrations in 
RBC supernatant were measured in duplicate using a commercial sandwich enzyme-linked 
immunosorbent assay according to the manufacturer’s guidelines.m Serum canine CRP 
was measured by a high throughput biochemical analyser at a commercial laboratory.n  
 
Statistical Analysis 
Data were analysed on an intention-to-treat basis. Statistical analysis was performed using 
commercially available software.o Significance was set at P<0.05. Baseline characteristics 
were described as median (Q1-Q3) or number (%), and were not statistically compared 
between groups.20, 21 Where multiple RBC bags were administered to an individual dog, 
RBC bag age and IL-8 concentrations were averaged across all bags administered. The 
average was then used for data analysis. If a dog was missing 24 h biomarker data due to 
death or discharge, RBC bag age and IL-8 concentration was excluded from analysis for 
any RBC bags transfused after 8 h. Due to highly skewed data, RBC bag age and IL-8 
concentration were compared between groups using Wilcoxon rank sum test. Data are 
reported as median (Q1-Q3).  
Distribution of temperature and biomarker outcomes was assessed by visual inspection 
of histograms and Q-Q plots. Log transformation was performed for right skewed data in 
order to approximate a normal distribution. Data were described as mean (95% 
confidence interval), or geometric mean (95% confidence interval) for skewed data. 
Concentrations of leukocytes, IL-6, IL-8, MCP-1, and CRP, and body temperature were 
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compared between groups over time using linear mixed effects models, with random 
effect of dog nested within treatment. A difference between groups in change over time 
was considered if there was a significant treatment-by-time interaction. Clinical outcome 
data were not compared due to inadequate sample size for this analysis however, 
summarised data are provided. 
 
4.4. Results 
A total of 139 dogs were prescribed RBC transfusions and hence eligible for inclusion 
between July 15, 2018, and January 5, 2019. Seventy-two dogs were excluded, leaving a 
total of 67 dogs enrolled in the study (Figure 1). Sixty-one dogs (NLR, n=27; LR, n=34) had 
completed data collection through 8 h, and were therefore included in the final analysis.  
 
Patient and transfusion characteristics 
Characteristics of the dogs in each group can be found in Table 1. The most frequent 
reasons for being prescribed a RBC transfusion were bleeding from an intra-abdominal 
mass and trauma (Tables 1S and 2S in Appendix 2 in supplementary material).  
Overall, 41 LR RBC bags and 37 NLR RBC bags were transfused (Table 2). There was no 
significant difference in age of transfused RBC bags between groups (P=0.22). Interleukin-
8 concentration was significantly higher in NLR RBC bags, compared to LR RBC bags 
(P<0.001, Table 2). All dogs received all RBC bags between 0 h and 8 h, with the exception 
of one dog in the LR group. That dog received two RBC bags prior to 8 h, and one bag 
between 8 h and 24 h, and as it was euthanised prior to 24 h, no data was collected beyond 
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8 h. All patients except one received RBC from only their allocated group. One dog in the 
LR group that was transfused a total of 4 RBC bags, was given NLR RBC as the fourth and 
final RBC bag. 
 
Figure 1. Flow chart of dogs included and excluded from randomisation into a clinical trial to 
receive leukoreduced or non-leukoreduced red blood cells (RBC). h: hours. 
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Table 1. Characteristics of dogs randomised to receive leukoreduced or non-leukoreduced red 
blood cell (RBC) transfusions 
Data is presented as either median [Q1-Q3] or number (percentage). 
 
Table 2. Red blood cell (RBC) bag characteristics and transfusion logistics for dogs randomised to 
receive leukoreduced or non-leukoreduced RBC transfusions 
Data is presented as either median [Q1-Q3] or number (percentage).  
† Compared between groups using Wilcoxon rank sum test, P=0.22  
‡ Compared between groups using Wilcoxon rank sum test, P<0.001  





Age (years) 10.5 [6.9–11.6] 10 [5–11.3] 
Sex   
     Male neutered 12 (35.3) 12 (44.4) 
     Male entire 5 (14.7) 3 (11.1) 
     Female entire 4 (11.8) 6 (22.2) 
     Female spayed 13 (38.2) 6 (22.2) 
Compatibility testing   
     Blood typed 31 (91.2) 26 (96.3) 
     Cross-matched 10 (29.4) 2 (7.4) 
Reason for transfusion   
     Bleeding intra-abdominal mass 18 (53) 9 (33) 
     Trauma 7 (21) 12 (44) 
     Coagulopathy 5 (15) 3 (11) 





Age of transfused RBC bags (days)† 21 [13–31] 25 [21–34] 
RBC bag interleukin-8 (pg/mL)‡ 19 [7-40] 266 [200-438] 
Dogs transfused with 1 RBC bag  30 (88) 23 (85) 
Dogs transfused with >1 RBC bags 4 (12) 4 (15) 
Dogs given all RBC prior to 8 hours* 34 (100) 25 (93) 
Quantity of RBC transfused (mL/kg) 13.6 [10.5-21.1] 13.3 [10.7-17.6] 
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Body temperature and inflammatory biomarkers  
Nine dogs in the LR group and 2 dogs in the NLR group did not have data collected at the 
24 hour time point, as they had been euthanised (n=8), or discharged (n=3). There was no 
significant difference between groups in change of temperature over time (P=0.12, Figure 
2). Ten dogs were removed from temperature analysis due to missing data (LR: n=7; NLR: 
n=3). No dogs had a rectal temperature ≥39.2 °C (>102.5 °F) at 0 h. Two dogs in each group 
had a rectal temperature ≥39.2 °C (>102.5 °F) at either 8 h or 24 h, or at both time points. 
Finally, there were no significant differences between treatment groups in change over 
time of leukocyte count (P=0.93), CRP (P=0.18), IL-6 (P=0.99), IL-8 (P=0.75), or MCP-1 





















Figure 2. Rectal temperature over time in dogs receiving a transfusion of either 
leukoreduced (LR) or non-leukoreduced (NLR) red blood cells. Temperature was 
assessed immediately prior to the start of transfusion (0 hours), then 8 hours and 24 
hours after the start of transfusion. Due to missing data, dogs were excluded from 
analysis at each time point: 0 h: LR n= 31, NLR n=27. 8 h: LR n=28, NLR n=26. 24 h: LR 







































Figure 3.  Inflammatory biomarker concentrations including A: Leukocyte Count, B: C-reactive 
protein, C: Interleukin-6, D: Interleukin-8, and E: Monocyte-chemoattractant protein-1, over time 
in dogs receiving a transfusion of either leukoreduced (LR, n=34) or non-leukoreduced (NLR, 
n=27) red blood cells. Blood samples were collected within 1 h of transfusion (0 hours), then 8 
hours and 24 hours after the start of transfusion. Nine dogs in the LR group and 2 dogs in the NLR 
group were not sampled at 24 hours. 
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Clinical outcomes 
Ten dogs (10/34, 29%) in the LR group and 4 dogs (4/27, 15%) in the NLR group were 
euthanised, with 6 LR RBC recipients and 2 NLR RBC recipients euthanised prior to the 24-
hour sampling time point. There were no natural deaths. Excluding euthanised dogs, the 
median length of hospitalisation for dogs in the LR and NLR groups were 2 (1–4) days and 
3 (2–4) days, respectively.  
 
4.5. Discussion 
We developed a successful protocol to enroll and randomise critically ill dogs into a two-
center, blinded, placebo-controlled clinical trial to assess the effect of leukoreduction on 
post-transfusion inflammation. We found no significant difference in change of 
inflammatory biomarker concentrations over time between LR and NLR RBC recipients, 
possibly due to biomarker concentration variability and small sample size. However, 
importantly, we have reported the feasibility outcomes for a study protocol that can now 
be used to power and design a follow-up larger multicenter clinical trial.  
Our trial protocol was novel in that the dedicated blood bank technicians randomised the 
allocation of RBC bags into LR or NLR at the time of blood collection, with no additional 
randomisation occurring at the patient level. We found that this protocol allowed for easy 
patient enrollment with no breach in blinding. With our method, there were always both 
LR and NLR bags of both dog erythrocyte antigen 1 positive and negative blood readily 
available to use within the blood bank. Dogs prescribed a transfusion received the oldest 
compatible available RBC bag, which allocated each dog to one of the two study groups. 
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Because all bags were clearly marked A or B, but otherwise identical in appearance, one 
dog could receive multiple bags of blood from within its original group allocation. This 
randomisation and blinding protocol prevented the main enrollment problems seen in a 
similar clinical trial, including missed enrollment due to lack of LR blood present in the 
blood bank, and excluded patients due to requirement for multiple transfusions.18 While 
our protocol led to all RBC-transfused dogs at the study sites to receive blood that had 
been prepared for the study, regardless of their enrollment in the study, the clinical 
equipoise between LR and NLR RBC precluded this from being of ethical concern. In 
consideration of planning a larger multicenter clinical trial focused on clinical outcomes, 
our protocol would be easy to implement at any veterinary institution with its own blood 
bank and dedicated blood bank technician.  
There was substantial baseline heterogeneity in inflammation in our study, reducing the 
power to detect differences in change over time. While a previously published pre-clinical 
trial showed a clear increase in inflammatory biomarkers from baseline after transfusion 
of NLR RBC that was attenuated with LR RBC, the dogs within that study were healthy and 
had minimal baseline variation in inflammatory biomarkers.5 Illustrating the challenge 
introduced with heterogeneity, a similar clinical trial in a small population of critically ill 
dogs with variable baseline inflammatory biomarker concentrations also found no 
difference in post-transfusion inflammatory biomarker concentrations between dogs 
transfused LR or NLR RBC.18 Data from the aforementioned study was not available during 
the planning of this clinical trial. While the wide variation in baseline inflammation in our 
small population likely contributed to our inability to reject our null hypothesis, we now 
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have adequate data to conduct a power calculation for a follow-up clinical trial, with either 
biomarker or clinical outcomes, while accounting for this baseline variability.  
Given our small sample size, we attempted to increase the potential of finding a difference 
between groups by excluding patients that were receiving or were likely to start receiving 
immunosuppressive drugs that might attenuate a post-transfusion inflammatory 
response. Immunosuppressants, notably the commonly-used class of glucocorticoids, 
suppress the acute inflammatory response by inhibiting transcription of a variety of pro-
inflammatory molecules such as cytokines, chemokines, arachidonic acid metabolites, 
and adhesion molecules.22, 23 Inhibition of the production of pro-inflammatory cytokines, 
or downstream signaling molecules such as CRP, could decrease the magnitude of any 
difference between groups.24 As this was a preliminary trial, we felt it prudent to limit 
variables causing additional heterogeneity of biomarker concentrations where possible. 
Due to this, our results may not reflect the clinical relevance of transfusing LR RBC in a 
population including dogs with immunosuppression. However, despite this exclusion, we 
still found no significant differences in inflammatory biomarkers between groups over 
time.  
Our randomisation and allocation protocols precluded us from controlling for the age of 
RBC bags transfused to enrolled patients. There is some evidence that older stored blood 
instead of fresh stored blood induces inflammation in recipients,25, 26 and leukoreduction 
may or may not attenuate this response.1, 4, 5 Thus, not controlling for RBC bag age may 
have introduced more variability into our population’s inflammatory response. However, 
we believe our trial best reflects clinical practice where variably-aged blood will be 
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available for any given transfusion, and therefore would provide the most relevant data 
regarding the effect of LR on post-transfusion inflammation. We found the median age of 
transfused RBC bag in our study was not different between groups, at 21 (14-31) days for 
LR and 25 (21-34) days for NLR. From previous in vitro analyses, we expected accumulation 
of IL-8 in NLR but not in LR RBC bags over time, with concentrations of IL-8 to be highest 
in older NLR bags.13, 15 Unsurprisingly, given our RBC bags were a median of 3 weeks old, 
we found significantly higher concentrations of IL-8 in NLR compared with LR RBC bags. 
Despite the difference in concentrations of transfused IL-8, we found no difference in 
inflammatory biomarker concentrations between recipients of NLR and LR RBC. While this 
may reflect that IL-8 is not the stimulus for a post-transfusion inflammatory response, it is 
also possible that this is a type 2 error, as discussed above. 
To optimise our ability to detect a difference between our treatment groups while also 
ensuring ethical treatment of our critically ill patients, we selected specific inflammatory 
biomarkers and limited sampling time points based on previous canine transfusion 
studies. Leukocytes and CRP were chosen because transfusion of LR RBC, compared with 
NLR RBC, to healthy dogs attenuated post-transfusion increases in these.5 We also chose 
to assess concentrations of IL-6 as the stimulus for CRP production,24 IL-8 given its 
propensity to accumulate in RBC during storage,15 and MCP-1 given evidence of marked 
elevation in critically ill dogs.27 We selected our two post-transfusion time points of 8 h 
and 24 h based on two studies assessing post-transfusion inflammation in healthy dogs, 
which reported peak concentrations of IL-6, IL-8, and MCP-1 at 6 hours, leukocytes at 12 
hours, and CRP at 24 hours post transfusion.1, 5 We felt our chosen time points would best 
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detect peak changes from baseline within the first 24 hours post-transfusion, without 
excessive sampling of blood. It is possible that between-group differences in inflammatory 
biomarker concentrations may have been missed if the peak fell outside of our selected 
time points. Also, it is possible we may have excluded relevant inflammatory biomarkers 
from our analysis, like tumor necrosis factor-α, IL-1α and IL-1β. Overall, more frequent 
sampling times or extending the spectrum of inflammatory biomarkers may have enabled 
identification of differences between treatment groups.  
We found no significant difference in the change in body temperature over time between 
groups. Body temperature was recorded to assess for the development of FNHTR. 
However, we had not considered the potential for patients to have external factors 
contributing to body temperature changes. Several of our enrolled patients developed a 
1°C change in body temperature over the 24-hour study period, which would have fit the 
definition of FNHTR. However, many of these patients were mildly hypothermic at 
baseline, as demonstrated by the summarised data in Figure 3. Both external active 
warming devices and resolution of shock would have contributed to increasing body 
temperature into a normal range. In addition, while blood sampling occurred as directed 
at all time points through hospital discharge or death, there was substandard compliance 
with recording temperature on the case report form at these time points, leading to 
several missing data points. Separate to these issues, our study was also underpowered 
to detect a between-group difference in development of FNHTR, given the likely low 
incidence of FNHTR in transfusion recipients.8 While many large retrospective human 
studies have demonstrated a significant reduction in FNHTR incidence after 
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implementation of leukoreduction, the effect size was small.28, 29 Future studies 
investigating the incidence of FNHTR with administration of LR compared with NLR RBC in 
dogs should plan to account for non-pyrexic changes in body temperature and enroll a 
larger sample.  
While our study was underpowered to find a difference in post-transfusion inflammatory 
biomarkers with the use of LR RBC, we propose that sample size for a follow-up larger 
clinical trial can be estimated using the CRP data from our study. Using the mean CRP from 
our LR and NLR groups at the 24 h time point, and the standard deviation of 50 from the 
NLR group, a sample size of 150 patients per study arm would give 80% power to detect 
a difference in mean CRP between 116.2 mg/L (NLR) and 100 mg/mL (LR) at α = 0.05.  C-
reactive protein is a preferred biomarker to measure in a large multicenter clinical trial for 
several reasons. Firstly, canine CRP assays are routinely available in many commercial 
veterinary laboratories, so they can be measured within the patient sample collection 
phase. Secondly, CRP reliably increases within 24 hours following transfusion in healthy 
dogs receiving NLR but not LR blood.5 This is different to the biomarkers IL-6, IL-8, and 
MCP-1, where no differences were found between healthy dogs transfused LR and NLR 
RBC in a separate experimental study.1 Finally, in people, CRP correlates with an increased 
risk of organ failure and death.30 If this holds true in dogs, CRP may become an important 
outcome measure in a population of critically ill dogs receiving transfusions. Thus, it is 
recommended that a follow-up larger multicenter clinical trial should compare CRP 
concentrations over time between critically ill dogs receiving LR or NLR RBC. Additionally, 
a future multicenter clinical trial could be sufficiently large enough to specifically evaluate 
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the incidence of FNHTR, while considering factors such as active warming, to address the 
aforementioned limitations. 
In conclusion, we developed a novel randomisation protocol and executed a successful 
two-center, randomised, blinded, controlled clinical trial to assess the effect of 
leukoreduction on post-transfusion inflammation in critically ill dogs. Although our study 
confirmed that concentrations of IL-8 were significantly lower in LR than NLR RBC bags, 
we found no difference in the post-transfusion inflammatory response in dogs receiving 
LR or NLR RBC, as measured by leukocyte count, IL-6, IL-8, MCP-1, and CRP concentration. 
The results of this study will be useful in designing and powering a follow-up larger 
multicenter clinical trial to assess an effect of LR on post-transfusion inflammation in 
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4.8. Appendices 
Appendix 1 = Case Report Form  
 
Date: _________________ 
ICY POLE STUDY: Blood Product Transfusion Record 






Donor ID: ___________ 
Blood type (circle): 
Canine     DEA 1 positive 
    DEA 1 negative 
Body weight: ____________ 
Blood type (circle): 
Canine    DEA 1 positive 
   DEA 1 negative 
GROUP (circle):   A       B 
ICY POLE Study Checklist 
ICY POLE Study No. __________ 
 
Collect T0 from the RBC Unit             
 
Collect T0 from the recipient 
 
START transfusion  
 
Collect T1 8 hours after START 
 
Collect T2 24 hours after START 
Send EDTA samples to VetPath  
Previous transfusion (circle): 
No       Yes 
Previous transfusion reaction 
(circle):     No         Yes (describe) 
___________________________ 
 
Cross-match performed (circle): 
No           Yes (if so, 
compatible to which donors): 
_______________                            
_______________                   
Blood product: RBC 
 
Transfusion start time: 
 
Transfusion finish time: 
 
Total volume infused: 
 
 










Or Doppler BP 
Administration rate 
(mL/hr) 
*** COLLECT ‘T0’ SAMPLE ***  
0       
+5       
+10       
+15       
+20       
+30       
+45       
+60       
+90       
+120       
+180       
+240       
T1*       
T2*       
* On the patient chart, circle T1 vitals and blood to be collected 8 hours after the start of transfusion, and T2 vitals and blood 
to be collected 24 hours after the start of transfusion 







ICY POLE STUDY 
 
1. Call on-call clinical study clinician (see roster) to process samples 
 
2. Fill out front of this transfusion record with patient info and ICY POLE study kit number. 
 
3. Choose next available RBC unit for transfusion (cross match first, if indicated).  
 
4. Circle group A or B on front of this transfusion record (Group letter will be on RBC unit)  Patient 
will remain in this group for the next 24 hours, receiving only blood from this group! 
 
5. Collect blood tubes from small zip lock T0 inside the study pack.  
 
6. Spike bag with giving set and aseptically remove 5 mL from injection port on the giving set line. 
Place in large RED TOP tube labelled “Bag” and place in blood fridge.  
 
7. Collect 4 mL blood from patient due to receive transfusion. Place 2 mL into GREEN TOP tube, 1 
mL into YELLOW TOP  tube, and 1 mL into PURPLE TOP tube 
 
8. Place these samples in the blood fridge until the on-call study clinician arrives.  
 
9. Record pre-transfusion vitals on the front of the transfusion record and place a continuous 
temperature probe in the patient. Zero pump volume so total volume can be recorded at end of 
transfusion. 
 
10. ASSIGN A VET STUDENT TO THE PATIENT! Let them know they have that patient as a top priority 
over the next 4 hours. They need to fully complete the transfusion record in detail. If they are due 
to go off shift, they must hand over to the next student or an ICU nurse before leaving. 
 
11. START the transfusion – record start time on front of the form.  
 
12. DURING TRANSFUSION: It is imperative that the patient vitals are recorded at 0, 15, 30, 60, 120, 
180, and 240 minutes after the start of the transfusion at a minimum (i.e. Take vitals at these 
times, even if the transfusion is completed). Also note any abnormalities as well as any treatments 
for these abnormalities in the lines below the vitals chart. 
 
13. FINISH transfusion – record time and total volume infused by pump on front of transfusion 
record. 
 
14. Patient vitals and blood samples are repeated 8 hours after start of transfusion (T1) and 24 hours 
after start of transfusion (T2). Repeat blood collection as written in step 6 above. Add blood 
samples to tubes within the small zip locks T1 (8 hours after transfusion start) and T2 (24 hours 






Appendix 2 = Supplementary results  
 
Table 1S: Histopathological diagnosis of splenic and hepatic masses from dogs (n=15) that 
received a transfusion of either leukoreduced (LR) or non-leukoreduced (NLR) red blood cells as 












Splenic hemangiosarcoma  2 2 
Hepatic adenocarcinoma  3 0 
Hepatic hemangiosarcoma 1 0 
Malignant splenic fibrous histiocytoma  1 0 
Splenic sarcoma  1 0 
Benign  
(n=4) 
Hepatic abscess  1 0 
Hepatic adenoma  1 0 
Splenic abscess  1 0 
Splenic nodular and lymphofollicular hyperplasia 1 0 
Metastatic 
(n=1) 
Hepatic and peri-renal undifferentiated carcinoma  0 1 
 
 
Table 2S: Cause for red blood cell (RBC) transfusion in dogs (n=34) that received leukoreduced or 
non-leukoreduced RBC as part of a randomised, blinded, controlled clinical trial  
 
 









Surgical losses  4 3 
Motor vehicle accident  2 7 
Post-rhinoscopy  1 0 
Dog fight wounds  0 2 
Coagulopathy  
(n=8) 
Anticoagulant rodenticide  4 3 
Disseminated intravascular coagulation post- 





Gastrointestinal hemorrhage 2 0 
Diabetic ketoacidosis 1 0 
Myelodysplasia 1 0 
Lymphoma 0 1 
Post-chemotherapy 0 1 




5. Chapter 5: Discussion and conclusion 
5.1. Discussion 
Our survey was the first to describe blood banking and transfusion practices of 
Australian veterinarians, and in accordance with our hypothesis, we found inconsistencies 
compared to what is recommended by experts in veterinary transfusion medicine. For 
example, while blood component therapy is recommended over whole blood transfusions 
by experts in transfusion medicine,1-3 through our survey we discovered that with the 
exception of veterinarians in specialty hospitals, most Australian veterinarians do not have 
routine access to dog and cat blood components. In addition, contrary to expert 
recommendations to administer type-specific blood and cross-match patients prior to 
transfusions,4-6 our survey revealed nearly half of surveyed practitioners do not 
compatibility-test dogs and over half do not test cats prior to blood transfusion. Finally, 
our survey found that more than half of respondents pre-medicate dogs and cats prior to 
transfusion. Due to the lack of evidence of a benefit in people and dogs, premedication 
prior to transfusion is not recommended by experts.7-11 These were some of the main 
breaks with expert recommendations we found with our survey of small animal 
practitioners. We postulate that potential explanations for these inconsistencies include 
lack of awareness of current expert advice, inability to adhere to expert recommendations 
due to financial constraints involved with maintaining blood bank inventory to ensure 
ready access to blood, and perhaps limitations in owner’s willingness to comply to the 
expense associated with ideal care. While there are several limitations to this survey, such 
as the possibility of multiple responses from veterinarians within the same clinic, a bias 
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towards transfusion practices in Western Australia, and an overall small sample size, this 
survey highlighted areas of veterinary transfusion medicine in Australia that can be 
improved. The information we gained from our exploratory survey will form the 
foundation on which we can build more in-depth investigations to unpack the motivations 
behind the current practices that lead them to differ from expert opinion. Future surveys 
could be designed to more specifically probe into reasons Australian veterinarians 
perceive limitations to administering transfusions. In addition, studies may also be 
designed to further investigate actual prevalence of transfusion reactions in Australian 
pets. Future directions to improving awareness of current expert recommendations 
include reviewing and improving the contents of transfusion medicine taught to 
veterinary students, including transfusion medicine chapters in international conferences, 
and having an open-access international consensus statement on veterinary transfusion 
practice. Ultimately, our goal will be to better align current veterinary transfusion 
practices in Australia with expert recommendations, to help decrease the risk of 
transfusion-related complications.  
While many transfusion-related complications may be avoided by adhering to best 
practice, some, including transfusion-triggered inflammation, can occur despite ideal 
blood banking and transfusion practices. Pro-inflammatory cytokines and storage lesions 
accumulate in blood products over time during storage,4, 12-19 causing transfusion-related 
complications in people and dogs.20-22 Ultimately, this increases recipient morbidity and 
mortality. Leukoreduction has been shown to successfully prevent accumulation of some 
pro-inflammatory cytokines and storage lesions in both human and canine blood during 
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storage.23-26 As such, transfusion of leukoreduced RBCs has been shown to decrease 
transfusion-related complications in people.27-34 Clinical trials in critically ill dogs showing 
such benefit were lacking, so we designed a study to determine if leukoreduction may 
provide a benefit to critically ill dogs. Our study compared concentrations of inflammatory 
biomarkers over time in critically ill dogs administered either leukoreduced or non-
leukoreduced packed RBCs, and found no significant difference in change of 
concentrations of inflammatory biomarkers in critically ill dogs that received leukoreduced 
and non-leukoreduced RBCs. The most likely cause for not finding a significant difference 
was attributed to a markedly heterogenous patient population coupled with a small 
sample size, which reduced our power to detect a difference between our treatment 
groups. It is also possible that we could have missed detecting a difference due to our 
choice of specific inflammatory biomarkers and sampling time points. Future clinical trials 
can be designed to study a homogenous population to improve our statistical power to 
detect a difference between treatment groups. While we did not find a specific benefit 
with leukoreduction in our small study population, we did successfully create a novel and 
easily actionable randomisation and blinding protocol that can be scaled up to perform a 
larger multicenter international study, powered to evaluate for differences in clinically 





In conclusion, our survey revealed current practice in blood banking and 
transfusion practices in Australian veterinarians was not aligned with veterinary expert 
recommendations. This could be one reason for the development of transfusion-related 
complications in dogs and cats. Although our clinical trial did not provide evidence that 
leukoreduction was able to decrease post-transfusion inflammatory response in a small 
heterogenous population of critically ill dogs, we were able to successfully design a novel 
randomisation and blinding protocol that will serve as a prototype upon which additional 
larger trials can be modelled to determine if leukoreduction can decrease the risk for 
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